Court Rulings Confirm Autism-Vaccine Link – But US Forbes Magazine’s “Scientist” Blogger Emily “Daisy May Fatty-Pants” Willingham Disagrees

You may decide to never ever trust anything written in the US Forbes magazine on anything [and not just autism] after reading this.

Emily Willingham writes a blog for Forbes magazine in the US claiming to be authoritative about “how science filters to consumers and how consumers make decisions about science“.  [Although how she claims to do that without qualifications or research to back up her claims to expertise in the area is another matter.]

Emily [or “Daisy May Fatty-Pants” as she called herself when starting out as a junior blogger in the little league], got pretty hot under the collar about an article in the Whiteout press entitled “Courts quietly confirm vaccines cause autism”.

So Emily “Fatty-Pants” wrote a piece for her Forbes blog “Court Rulings Don’t Confirm Autism-Vaccine Link” [9th September 2013].  In that blog post Emily makes claims which are untrue.  So CHS is setting the record straight to help Emily understand that writing biased blogs which mislead consumers aboutscience” whilst claiming to do the reverse is something of a “no-no“.

Forbes magazine has a track record of backing writers who claim vaccines simply do not and cannot cause autistic conditions whilst at the same time such writers will typically claim what causes them is a mystery [which is a wholly contradictory and illogical position to take].  If you claim not to know what causes autistic conditions then you might have some difficulty claiming you do know vaccines never do.

We only have to take one paragraph of Emily “Fatty-Pants” Willingham’s blog to show it makes numerous claims which are not true – so misleading the consumers she is claiming to be putting right on the facts about science:

The centerpiece of the “courts confirm” article is the 2012 finding of a local Italian court that a child was diagnosed with autism a year after receiving an MMR. The court, in linking the two things, relied very heavily on the retracted and fraudulent 1998 Wakefield MMR Lancet paper and the testimony of a single physician, hired by the plaintiff’s attorney (widely known for advising parents on how to avoid compulsory vaccinations). The physician, Massimo Montinari, it seems, has written a book on how vaccines cause autism and peddles an autism “cure” that he’s devised.”

If we dealt with all the false claims in her entire Forbes blog this would be an extremely long CHS article.  The centerpiece of the “courts confirm” article was not the Italian case but two US cases.  

Emily “Fatty-Pants” Omitted Articles Centerpieces – Two US Court Cases – Children Awarded US$ Millions

The Whiteout Press story centered on two US Court decisions where two US children who developed autistic conditions after receiving MMR vaccines were awarded millions of US dollars in compensation. So Emily “Fatty-Pants” Willingham’s consumer readers were very seriously misled.

The Whiteout Press centerpiece was not the claimed Italian Court decision about the little Italian boy Valentino Bocca who developed autism after receiving the same MMR vaccine given to children in the USA – Merck’s MMR II.

Emily “Fatty-Pants” False Claim – Italian Court “Relied Heavily” on Biased Testimony of Plaintiff’s Expert Physician

Emily “Fatty-Pants” made another completely untrue claim that “[t]he court, in linking the two things, relied very heavily on ….. the testimony of a single physician, hired by the plaintiff’s attorney (widely known for advising parents on how to avoid compulsory vaccinations). The physician, Massimo Montinari …“.

The Court appointed its own independent expert to write an independent report for the Court.  The Court relied on the report of its own independent expert.  This was not an expert hired by Valentino Bocca’s attorney.  So again, Emily “Fatty-Pants” seriously misled her consumer readers at Forbes magazine on issues of science.

The Court appointed independent expert was also not anyone called “Massimo Montinari” or anything even close.  So again Emily “Fatty-Pants” Willingham seriously misled her consumer readers at Forbes magazine on issues of science.

What Did The Court Appointed Independent Expert Rely On?

In a wide-ranging review of the literature the independent expert cited a large number of medico-scientific papers and publications.  These included publications from the Global Advisory Committee on Vaccine Safety (GAVCS), World Health Organization, the US Institute of Medicine [2001 and 2004], Brent Taylor, Fombonne, Madsen and many more too numerous to list here.

So yet again Emily “Fatty-Pants” Willingham demonstrates how she very seriously misled her consumer readers on their decisions about science and bases her misinformation on invention from anonymously published blogs.

Emily “Fatty-Pants” False Claim – The Court Relied Heavily on Wakefield’s MMR Lancet Paper

Another outright falsehood by Emily “Fatty-Pants” Willingham was the claim “The court, in linking the two things, relied very heavily on the retracted and fraudulent 1998 Wakefield MMR Lancet paper“.  That is purely and simply invention which Emily “Fatty-Pants” Willingham appears to have quoted from a blog she linked to which is published anonymously.  Bit of a Big Oops there for Emily “Fatty-Pants”.

The Italian Court did not rely on the Wakefield paper “heavily” or at all.

Emily “Fatty-Pants” Failed to Tell Her Consumer Readers The Italian Government Did Not Dispute Merck’s MMR II Vaccine Caused The Child’s Autism

Emily “Fatty-Pants” misled her consumer readers in making their decisions on issues of science in that the evidence in the Valentino Bocca case was sufficiently clear that the Italian Health Ministry did not contest that the MMR vaccine had caused little Valentino Bocca’s autism.  They instead contested his entitlement to compensation because the vaccination was not compulsory [but of course heavily promoted to Italian parents to make them feel guilty if they did not vaccinate their child].

Emily “Fatty-Pants” Did Not Even Read the News Article She Criticised on Forbes

Worse is whilst Emily “Fatty-Pants” linked to a blog she relied on as her source Emily “Fatty-Pants” failed completely to link to the news story she was writing about.  She did link to a different blog which did not carry the original Whiteout Press article but a reblogged different and clearly edited version.

And yet even worse still for Emily “Fatty-Pants” is that it seems she did not even read the article at all.  She cited it by an incorrect title – omitting the word “quietly“.  That is what the blog she cited as her source did – used that incorrect title – omitting the word “quietly“.  So it looks very much like Emily “Fatty-Pants” just read the anonymous blog she used as her source and not the article she claimed to criticise at all.

The blog Emily “Fatty-Pants” cited, SkepticalRaptor is one of the dime-a-dozen negative “skeptic” attack blogs pumping out misinformation about health issues, contributing nothing of value to human knowledge, whilst claiming things like “hunting pseudoscience in the internet jungle“.  And like a bird-of-a-feather Emily “Fatty-Pants” claims to write about “how science filters to consumers and how consumers make decisions about science” with no proper sources to back it up – but plenty of invention and hot air.

And it gets worse.

Emily “Fatty-Pants” Missed Mentioning Another of the Article’s Centerpieces

A centerpiece was also this – which Emily failed to mention at all – and which led directly to the article being published:

It was a regular reader named Kathleen that brought this ongoing story to our attention here at Whiteout Press. When asked what her connection to the vaccine-autism battle was, the young reader replied, “I just researched it for a school project a while back and then I stayed on top of it, until I couldn’t stand it anymore. I’m not a parent, nor do I belong to any organization – a mere outside observer.

This reader isn’t alone. The news that vaccines cause autism has spread across the US despite a coordinated media black-out. She takes her concerns one step further explaining, “All I want is to see this information where the public can access it. I’ve looked everywhere, and no one gives this dire Wakefield situation even ONE small mention.” She goes on to give us another motivation for her activism, “In Washington State, where I’m from, vaccines have become mandatory for school children, which is very frightening!

Emily “Fatty-Pants” Calls Wakefield’s Paper Fraudulent But Fails to Mention it is Just An Allegation And Is Being Contested in the Texas State Court

Emily “Fatty-Pants” use of “fraudulent” is subject to defamation proceedings in the Texas State Court against the British Medical Journal.  She failed to mention that at all which is a bit of an oversight and is misleading to your consumer readers when making their decisions about science.  If any of them get into trouble with the law later for repeating that can they sue Emily for misleading them whilst claiming to be an authority on science and how consumers made decisions about science?

We thought we ought to mention that “fraudulent” appears to be an allegation made by the BMJ which may have been made without looking too carefully at the facts first.  The BMJ’s Texas “Anti-SLAPP” statute counter suit, predicted by the blogosphere to put an end to the case instantly as baseless, appears to have vanished and been dropped by the BMJ.  That seems to add some credence to the possibility that “fraudulent” is a less than appropriate description.  Maybe Emily you might care to mention that as a matter of accuracy?  But then it is Forbes magazine you write for and if we go by your blog then, who knows, maybe accuracy is not Forbes strong suit?

Emily “Fatty-Pants” Defames An Italian Doctor Too

Defamation seems to be a bit habit forming for Emily.  It appears there is an Italian doctor Massimo Montinari who has helped hundreds of children and families with treatments which have been working for many doctors in the US, UK and around the world: Vaccine and autism, alarm or psychosis? October 22, 2012 L’Unità

‘Good’ 5-in-1 vaccine kills 5 times more kids than anything else – “The unfortunate story of 37 deaths from a ‘good vaccine'”

CHS’ ED’S NOTE:  Infant deaths in India associated with this 5-in-1 vaccine [DPT, hepatitis B, H influenza b] are five times greater than the all-cause mortality rate.

Unlike the American Academy of Pediatricians, the British Medical Association and others like them who defend vaccines in general come what may against protestations of their customers – parents on behalf of their vaccine injured children – the Indian Academy of Pediatricians is asking embarrassing questions about this vaccine.  You can read them in this article.

Following article is By Jacob Puliyel via Indo-Asian News Service

The unfortunate story of 37 deaths from a ‘good vaccine’

Dr Puliyel is Head of Pediatrics at St Stephens Hospital, Delhi. He is a member of India’s National Technical Advisory Group on immunization and has published extensively on vaccines.  See http://jacob.puliyel.com

On October 11, two children died in Kashmir after receiving the Pentavalent vaccine, taking to six the total deaths there in one week and to eight the deaths over the last three weeks. According to reports appearing in local newspapers, the deaths were said to be an allergic reaction to the vaccine. These deaths come on the heels of a press release from the health ministry on October 10 that a committee that looked into the 15 deaths in Kerala after vaccinations has said they were not caused by the vaccine but were coincidental deaths. The press release also announced that the Pentavalent vaccine is to be rolled out nationwide. A week earlier, another ministry spokesperson had admitted there had been 29 deaths all over the country following the vaccine. The figure has now ballooned to 37.

The 29 deaths had happened when 82 lakh doses have been administered (and about 27 lakh children have been immunized). This works out to more than one death per 100,000 vaccinated and that 300 children would die each year from the vaccine when the birth cohort is vaccinated. It must be borne in mind that the adverse events are picked up by a system of passive surveillance which according to the US FDA picks up only a tenth of the real number of adverse events.

Co-morbidity as cause of death

It has been suggested that some of the deaths in Kerala had happened in children with an underlying heart disease. Many children who died in Sri Lanka after receiving the same vaccine also had a similar heart condition. Had they not been vaccinated, the death rate from the vaccine would have been less.

However this is no practical proposition. Vaccinations are given in distant rural areas by health workers who are barely literate. The detection of heart murmurs by auscultation is a skill that many pediatricians have to hone over many years of training. In the absence of such training for all vaccinators, can we justify continuation of the vaccination programme?

In Sri Lanka vaccination was stopped after five deaths. Under pressure from international organizations the programme was restarted. After that, there have been 12 more deaths. Dr. Yogesh Jain, who has filed a PIL in the Supreme Court, has sought the court’s oversight to prevent such pressures from influencing decision-making in India.

The deaths from vaccine must be seen in the context of hard data from the best study on Hib (Haemophilus influenzae type b bacteria) in the country called the Minz study which suggested that some 175 children die from Hib meningitis in the birth cohort over five years and perhaps an equal number from Hib pneumonia. These figures from this large, meticulous community based study done in a population of 600,000 with house visits every two weeks and conducted over two years are clearly inconvenient. This is a case of the cure (vaccine deaths) being worse than the disease. The government seldom quotes the Minz study data, but relies instead on estimates that are not based on empirical evidence.

Central team declares vaccine safe in Kashmir

With practiced efficiency, after the eight deaths in Kashmir, a central team under Dr. N.K. Arora, who works for Inclen Trust, went to the state, visited the hospital and the homes of the dead children and issued a press release that there was no conclusive evidence that the deaths were due to the vaccine. Septicemia, pneumonia and meningitis were blamed, without explaining how children who were completely asymptomatic and well enough to be given routine preventive vaccination by healthcare personnel, could die of septicemia or pneumonia immediately afterwards. In other words, how could children gasping for breath with pneumonia or in shock due to septicemia and about to die in the next few hours be given Pentavalent vaccine by the healthcare personnel?

To be sure that the vaccine is the cause of a reaction, the same reaction must recur in the same person if he/she is given the same vaccine a second time. As this type of re-challenge is impossible when the reaction results in death, the expert team declares that “causative relation to immunization cannot be established with certainty”. It is nearly as if we are saying we will not believe the vaccine is “causative related” unless one child is resuscitated from the dead and then re-challenged to see if he will die a second time!

We need to use the same strict criteria and apply the same burden of proof when we say the deaths are due to Sudden Infant Death Syndrome (SIDS) or due to co-morbidity or due to preexisting septicemia or pneumonia. This we do not do.

Posers from the Indian Academy of Pediatrics

The Indian Academy of Pediatrics (IAP) recently held a meeting to look into the deaths and posed the following questions to the health ministry:

* As the peak incidence of SIDS occurs in early infancy, a close temporal relationship between this and receiving Pentavalent vaccine is expected by simple chance and, therefore, it may not be right to attribute the deaths in Kerala to SIDS.

* The deaths attributed to SIDS in Kerala are five times greater than the all-cause mortality rate in the state. What is the possible explanation for this spurt of deaths after introduction of Pentavalent vaccine?

* The peak age of SIDS is the third month (corresponding to the second dose), but the majority of deaths were reported after the first dose.

* The co-morbid conditions resulting in death following vaccination have not been clarified.

* Why the vaccine is being given to sick children is not explained.

* Underlying congenital heart diseases used to explain away the deaths were not serious enough to cause cardiac failure and death.

* Some children had high fever and excessive crying; some had convulsions after vaccination which can definitely be attributed to adverse events following immunization.

* Autopsies suggested hypersensitivity and shock – how should that be interpreted? Does it mean hypersensitivity to the vaccine?

The IAP discussed these with Dr. Ajay Khera, deputy commissioner (Maternal and Child Health) at the health ministry, who was unable to give any clarifications saying the final report of the enquiry committee on the deaths was awaited.

Yet an IAP press release after the meeting endorsed the vaccine in spite of the unanswered questions!

If answers to these straightforward questions are not known to the health ministry, how can we push the vaccine in the rest of the country?

We need to understand that the mandate of the health services and doctors is to protect the lives of children and not to promote vaccines of doubtful utility and safety.

(10.10.2013 – Jacob Puliyel is Head of Pediatrics at St Stephens Hospital, Delhi. He is a member of the National Technical Advisory Group on immunization and has published extensively on vaccines. He can be reached at puliyel@gmail.com)

Silent Epidemic – New Documentary Film About Diseases Caused by Vaccines – Production By US Broadcaster Gary Null

This new Gary Null documentary – view it below – is only available for viewing online on Youtube for a limited time.  [Gary Null broadcasts on PRN and on WBAI].

In the developed world we have the sickest generations of children – with many new chronic disorders and the highest levels of vaccinations and vaccines ever.

This is not coincidence.  Vaccines affect the normal functioning of your and your child’s immune system and cause chronic disorders in a significant proportion of the population.  The medical profession remain in denial despite 98 in 100 adverse drug reactions going unreported: “Spontaneous adverse drug reaction reporting vs event monitoring: a comparison” Journal of the Royal Society of Medicine Volume 84 June 1991 341.

And in Century 21 we do not have effective treatments for the most basic of childhood illnesses.  Millions in the third world die despite the vaccination programmes – they get disease because they do not have clean drinking water, adequate sanitation or diet and we give them vaccines instead.

UPDATE SUNDAY 6TH OCTOBER 2013:  THE FULL 1 HOUR 48 MINUTE DOCUMENTARY IS NOW ONLY FOR PRIVATE VIEWING ON YOUTUBE BUT IT HAS BEEN REPLACED WITH THE FOLLOWING 34 MINUTE PREVIEW VERSION:

—–

THE FULL 1 HOUR 38 MINUTE DOCUMENTARY IS LINKED TO HERE IN CASE IT GOES BACK UP ON YOUTUBE:

—–

Political Manipulation + Unneeded Vaccines = Seriously Harmed Children & No Legal Protection – Simple Video Explains

A new short video [5 mins] from the US Canary Party shows simply how vaccine manufacturers rushed to bring out new vaccines after political manipulation created a system which insulate them from the consequence of harm to children and families and the people end up paying in all ways:

______________

7 Deaths In Bill Gates Foundation Funded HPV Vaccine Trials – Trials Were “Child Abuse” Says Parliamentary Panel – India, The Hindu

When reading the following ask yourself why the European and US news media do not report these issues.  They exist worldwide.  Which political systems are more corrupt: the developed west or the emerging nations?

Panel raps government over clinical trials, lapses Rupali Mukherjee, Times of India Aug 31, 2013

MUMBAI: In a further indication of the rot in the country’s healthcare system, a parliamentary panel has rapped the government for gross irregularities in drug trials, under-reporting and lapses in monitoring serious adverse events and lethargy in safeguarding health, in studies on cervical cancer prevention vaccine by a US-based non-governmental agency. Charging the government for inaction, the parliamentary committee on health says in a report that the issue has been diluted with no accountability fixed on erring officials for serious violations committed in the studies which led to the death of hapless tribal children three years back.”

A Businessworld [India] report included the following quote from the Parliamentary committee report:

Cervical Cancer Clinical Trials Violated Norms: Panel – Businessworld 30 Aug, 2013

Parliamentary panel seeks action against wrong-doers and wants government to tighten the regulatory vigil further

“Its sole aim (the conduct of trials) has been to promote the commercial interests of HPV vaccine manufacturers who would have reaped windfall profits had PATH been successful in getting the HPV vaccine included in the UIP (universal immunisation programme) of the Country”, the panel noted, calling it “a serious breach of trust by any entity” as the project involved life and safety of girl children and adolescents who were mostly unaware of the implications of vaccination.

The following report appeared today in The Hindu:

It’s a PATH of violations, all the way to vaccine trials: House panel – By Aarti Dhar – The Hindu 2nd September 2013

Committee questions roles of ICMR, Drug Controller in the “intriguing” 2010 episode

Accusing the international organisation PATH (Programme for Appropriate Technology in Health) of exploiting with impunity the loopholes in the system during a trial of Human Papillomavirus (HPV) vaccines, a parliamentary panel has also questioned the roles of the Indian Council of Medical Research and the Drug Controller-General of India in the entire episode.

The issue pertains to trials conducted by two U.S.-based pharmaceutical companies through PATH on tribal school girls in Khammam district in Andhra Pradesh and Vadodara in Gujarat in 2010. The trials were stopped only after the matter received media attention following the death of seven girls.

In its report on “Alleged Irregularities in the Conduct of Studies using HPV Vaccines by PATH in India” presented to Parliament, the committee has said ICMR representatives apparently acted at the behest of PATH in promoting the interests of the vaccine manufacturers, and recommended that the Health Ministry review the activities of the functionaries of the Council involved in the PATH project

As for the DCGI, the approvals of clinical trials, marketing approval and import licences by the agency “appear to be irregular” and its role “in this entire matter should also be inquired into.”

The Department of Health Research/ICMR “have completely failed to perform their mandated role and responsibility as the apex body for medical research in the country. Rather, in their over-enthusiasm to act as a willing facilitator of the machinations of PATH, they have even transgressed into the domain of other agencies which deserves the strongest condemnation and strictest action against them.”

The committee failed to understand why the ICMR “took so much interest and initiative in this project when the safety, efficacy and introduction of vaccines in India are handled by the National Technical Advisory Group on Immunisation.”

How could the ICMR commit itself to supporting “the use of the HPV vaccine” in an MoU signed in 2007, even before it was approved for use in the country, which actually happened in 2008? The committee also questioned the ICMR’s decision to commit itself to promoting the drug for inclusion in the Universal Immunisation Programme before any independent study on its utility and rationale of inclusion in the UIP was undertaken.

Describing the entire matter as “very intriguing and fishy,” the committee said the choice of countries and population groups (India, Vietnam, Uganda and Peru); the monopolistic nature, at that point of time, of the product being pushed; the unlimited market potential and opportunities in the universal immunisation programmes of the respective countries “are all pointers to a well-planned scheme to commercially exploit a situation.”

Had PATH been successful in getting the HPV vaccine included in the universal immunisation programme of the countries concerned, windfall profits would have been generated for the manufacturer(s) by way of automatic sale, the committee said. It asked the government to take up the matter with these countries through diplomatic channels.

Flouting ethics

Drawing attention to gross violation of ethics during the conduct of trials, the committee members said that in Andhra Pradesh out of 9,543 consent forms, 1,948 had thumb impressions, while hostel wardens signed 2,763 others. In Gujarat, out of 6,217 forms, 3,944 had thumb impressions. The data revealed that a very large number of parents/guardians were illiterate and could not even write in their local language, Telugu or Gujarati.

It was shocking to find from one of the reports that out of 100 consent forms for Andhra Pradesh, project signatures of witnesses were missing in 69 forms. In many forms there were no dates. One particular person had signed seven forms. In fact, the legality of the State government directing headmasters of all private/government/ashram/schools to sign the consent forms on behalf of parents/guardians was highly questionable. The absence of photographs of parents/guardians/wardens on consent forms and of signatures of investigators, the fact that signatures of parents/guardians did not match with their names; and the date of vaccination being much earlier than the date of signature of parents/guardian in the consent forms spoke of grave irregularities, the report said.

The committee said PATH should be made accountable and the government should take appropriate steps in the matter, including legal action against it for breach of laws of the land and possible violations of laws of the country of its origin.

Describing this act of the PATH as a clear-cut violation of human rights and case of child abuse, the Committee has recommended that the National Human Rights Commission and the National Commission for Protection of Children Rights take up this matter. The National Commission for Women should also take suo motu cognisance of this case as all the poor and hapless subjects were female.

The Health Ministry should report the violations indulged in by PATH to the World Health Organisation and the United Nations Children’s Fund so as to ensure that appropriate remedial action was initiated worldwide, the committee said.

All Studies Claiming No MMR Vaccine-Autism Link Invalid – According to Merck’s Vaccine Director, former US CDC Director & the US HRSA

A recent article in the Whiteout Press appears to have reignited the debate about vaccines causing autism and has now been reported  by Fox News in Austin Texas.  But what both appear to overlook is the direct evidence from leading US health agencies and health officials which discredits all the prior evidence they have used and which is still being used on the internet and in the media to claim there is no autism-MMR vaccine link.  [Full quotes and links below].

Fox News in Austin Texas reported yesterday on the Whiteout Press article: Article stirs autism and vaccine debate Aug 15, 2013 By Noelle Newton KTBC Fox 7 Austin Texas USA.  And here is the Whiteout Press article:  “Courts Quietly Confirm MMR Vaccine Causes Autism” 27th July 2013.

Here is the problem for health officials now.  The US Heath Resources Services Agency and vaccine maker Merck’s vaccine division Director Julie Gerberding when heading up the US Centers for Disease Control as its Director both separately confirmed on and to national broadcast US news channels back in 2008 that any vaccine can cause an autistic condition [full quotes and sources below]. 

That confirmation immediately made completely invalid and useless all the “tobacco-science” statistical studies health officials had used to claim there was no connection between a child developing autism from the MMR vaccine.

Because researchers claimed to find no difference they assumed no link.  But they found no link because all those studies were intentionally carried out on the basis that only the MMR vaccine was a cause of autism and not all vaccines.

So now all those previous studies compared kids with autism who had MMR vaccine against kids with autism who had other vaccines and got autism from the other vaccines.  If you go shopping and compare all the candy in one store with all the candy all other stores all you will find is that its all candy.  Some might be Hersheys and some not.  But it is still candy.  Autistic conditions are like candy just in the sense there are all kinds and flavors but in a spectrum.  Of course that is where the similarity ends because the spectrum of autistic conditions is from the most debilitating to the least.  There is nothing sweet or attractive about that.

And if you want evidence of this then watch the British rate of childhood autism diagnoses increase with each change in the vaccine schedule.  This is a chart from a peer reviewed paper by US authors and researchers which only looked at the MMR vaccine and not the other vaccines. 

You can see the MMR vaccination rate is stable throughout [see nearly horizontal black line near top of the chart] but the autism risk jumps up [see red line on the chart].  Here at CHS we have added the notes showing when the changes to the British vaccine schedule took place.  With each change the risk of an autism diagnosis for children increased substantially:

CLICK GRAPH – OPENS LARGER ONE IN NEW WINDOW

Aut_Inc_vs_vax_prog

The graph above is adapted from a 2001British Medical Journal paper by Jick et al: Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis” BMJ 2001; 322 : 460 – 463 24 February.

The admissions by the US CDC Director Julie Gerberding and those by the US HRSA were not given voluntarily.  They only confirmed the true position when put under pressure by the media in 2008 when the Hannah Poling story broke about the US Court compensating a little girl who became autistic after getting NINE vaccines ALL ON THE SAME DAY.

But everyone overlooks that and the same old junk studies are being quoted all over the media and internet as evidence there is no link when they are completely useless as evidence for that proposition.

And then some studies looked for higher autism rates in the MMR vaccinated-autism kids. That is like looking to see whether under the wrapper of one brand like Hershey’s there is chocolate candy and under the wrappers of other brands like M&M’s it is chocolate candy or something of a different flavor or sweeter or less sweet.

The authors of the study into the British autism increase even admit the graph [see above] shows there must be environmental factors other than the MMR involved in the increases claiming [emphasis added]:-

“... the data provide evidence that no correlation exists between the prevalence of MMR vaccination and the rapid increase in the risk of autism over time. The explanation for the marked increase in risk of the diagnosis of autism in the past decade remains uncertain. ….. The increase ….. could be due to …… environmental factors not yet identified.

The data show when correlated with major changes in the UK childhood vaccination programme the most likely “environmental factors not yet identified” are the vaccines.  With each major change to the UK’s childhood vaccination programme cases of childhood autism increased substantially.

This is how the risk of a diagnosis increased [this is just childhood autism diagnoses – Aspergers is not included – note that 70% of UK ASDs are Aspergers]:

  • it first increased by 3 times with the introduction of the MMR vaccine in October 1988 [from between 1 to 4 in 10,000 it increased to 12 in 10,000];

As anyone can see from this, the studies needed to be done are comparing the total health of vaccinated kids with never vaccinated kids.   But the US CDC will never do them because never vaccinated kids are much healthier so showing the vaccine programmes pursued by the US CDC for decades do more harm than good.  The argument used to claim the studies cannot be done is junk – they claim it is unethical to prove a vaccine is safe to use or dangerous so we cannot do the studies.  This is on the basis it is unethical not to vaccinate a few kids to make sure millions upon millions of kids will be safe.  It cannot be unethical if done with consent and where the comparatively few kids who are not vaccinated can still be vaccinated after the studies are over. Surely, if “herd immunity” worked those few would still be protected by it?

And of course it is unethical to give any drug of unproven safety to any child.

Here is what the US HRSA told CBS news reporter Sharyl Attkisson back in 2008 about children compensated for injuries caused by a vaccine – any vaccine – not simply the MMR vaccine:

We have compensated cases in which children exhibited an encephalopathy, or general brain disease. Encephalopathy may be accompanied by a medical progression of an array of symptoms including autistic behavior, autism, or seizures.Text of May 5th 2008 email from US HRSA to Sharyl Attkisson of CBS News]

So according to the HRSA vaccines cause encephalopathies [general brain injuries] which result in autism and/or seizures in children.

Here is what US CDC Director Julie Gerberding said on national US broadcast TV back in 2008:

Now, we all know that vaccines can occasionally cause fevers in kids. So if a child was immunized, got a fever, had other complications from the vaccines. And if you’re predisposed with the mitochondrial disorder, it can certainly set off some damage. Some of the symptoms can be symptoms that have characteristics of autism.

HOUSE CALL WITH DR. SANJAY GUPTA – Unraveling the Mystery of Autism; Talking With the CDC Director; Stories of Children with Autism; Aging with Autism – Aired March 29, 2008 – 08:30   ET

You can even watch Gerberding saying it to Dr Sanjay Gupta of CNN here on YouTube.  If you watch the video [below on this page] you will then realise Dr Julie Gerberding is personally knowingly responsible for the biggest longest running programme of child abuse in the history of the planet – knowingly causing autism in hundreds of thousands of US children using vaccines [currently around 1 in 50 US kids depending on State]- and when she was in a position to stop it dead.  She then left the CDC and continued where she left off to join vaccine maker Merck as its vaccines division Director.  The CDC was officially castigated by the US Senate in an official report CDC Off Centeras an agency which “cannot demonstrate it is controlling disease“  but which was managing to spend US$11 billion in US tax dollars every year not doing what even its name says it is supposed to – Center for Disease Control.

********** – **********

FOR THOSE WHO WANT TO READ IT HERE IS OUR PREVIOUS ARTICLE REPORTING THE FULL ISSUE

Vaccination Causes Autism – Say US Government & Merck’s Director of Vaccines

Posted on June 30, 2010 by ChildHealthSafety

A New Scientist article 29 June 2010 by Jim Giles states:-

We still do not know what causes autism.

Desperate measures: The lure of an autism cure

That is not correct. Here we set out four ways autistic conditions are caused and confirmed by statements from the current President of pharmaceutical giant Merck’s Vaccines Division, by US Government agencies, by the US Federal Court and in formally published academic journal papers.

If you read nothing else we strongly recommend you read this PDF Download – Text of May 5th 2008 email from US HRSA to Sharyl Attkisson of CBS News].  In it the US Health Resources Services Administration [HRSA] state to CBS News reporter Sharyl Attkisson

We have compensated cases in which children exhibited an encephalopathy, or general brain disease. Encephalopathy may be accompanied by a medical progression of an array of symptoms including autistic behavior, autism, or seizures.” [Text added 10 April 2011]

The first known cause of autism was rubella virus. So not only is New Scientist an unreliable source of information, this cause of autism has been known since the 1960s. And rubella virus is one of the three live viruses in the MMR vaccine.

… rubella (congenital rubella syndrome) is one of the few proven causes of autism.“  Walter A. Orenstein, M.D. US as Assistant Surgeon General, Director National Immunization Program in a letter to the UK’s Chief Medical Officer 15 February 2002.

rubella virus is one of the few known causes of autism.” US Center for Disease Control.
“FAQs (frequently asked questions) about MMR Vaccine & Autism”  [ED 8/Apr/12: This is the web archive of the CDC page – you will need to search in or scroll down the page to see the text.  As papers cited on the original page by the CDC as evidence for no link with the vaccine have been steadily discredited it seems the CDC has decided to remove the page and it seems someone has been deleting the archived versions of the page from the web archive too].

rubella can cause autismThe Pediatrician’s Role in the Diagnosis and Management of Autistic Spectrum Disorder in Children – PEDIATRICS Vol. 107 No. 5 May 2001

Journal references:

Chess, S. Autism in children with congenital rubella. J Autism Child Schizophr. 1, 33-47 (1971).

Chess S. Follow-up report on autism in congenital rubella. J Autism Child Schizophr. 1977;7:69 –81

Ziring PR. Congenital rubella: the teenage years. Pediatr Ann. 1997;6: 762–770

People who are pre-disposed to have a mitochondrial dysfunction can develop autistic conditions following vaccination.  The current President of Merck’s Vaccines Division, Julie Gerberding confirmed to CBS News when she was Director of the US Centres for Disease Control that:

….. if you’re predisposed with the mitochondrial disorder, it can certainly set off some damage. Some of the symptoms can be symptoms that have characteristics of autism.

HOUSE CALL WITH DR. SANJAY GUPTA – Unraveling the Mystery of Autism; Talking With the CDC Director; Stories of Children with Autism; Aging with Autism – Aired March 29, 2008 – 08:30   ET

Mitochondrial dysfunction is claimed to be “rare” but is not.  It can apply to a minimum of 20% of cases.

And this was said when Gerberding was then head of the US Centres for Disease Control – budget US$11 billion.  It followed from  award winning author and journalist David Kirby breaking the story of the Hannah Poling case, secretly settled by the US Government.  It was after this story broke that it started to be acknowledged that autism has an “environmental” cause and is not solely an “internal” condition [ie not determined solely by genetics]: AUTISM – US Court Decisions and Other Recent Developments – It’s Not Just MMR

[Gerberding went from the US agency charged with promoting vaccines [CDC] directly to become vaccine maker Merck’s Director of Vaccines Division: Dr. Julie Gerberding Named President of Merck Vaccines21 Dec 2009 – Merck & Co., Inc.

Autistic conditions can result from encephalopathy following vaccination.  The US Health Resources and Services Administration (HRSA) confirmed to CBS News that of 1322 cases of vaccine injury compensation settled out of court by the US Government in secret settlements:-

We have compensated cases in which children exhibited an encephalopathy, or general brain disease. Encephalopathy may be accompanied by a medical progression of an array of symptoms including autistic behavior, autism, or seizures.[PDF Download – Text of email from US HRSA to Sharyl Attkisson of CBS News]

CBS News Exclusive: Leading Dr.: Vaccines-Autism Worth Study Former Head Of NIH Says Government Too Quick To Dismiss Possible Link – WASHINGTON, May 12, 2008

Vaccine Case: An Exception Or A Precedent? – First Family To Have Autism-Related Case “Conceded” Is Just One Of Thousands – CBS News By Sharyl Attkisson WASHINGTON, March 6, 2008

Measles and mumps are two of the three live viruses in the MMR vaccine. Exposure to live measles or mumps viruses can cause encephalitis:-

measles and mumps can cause significant disability, including encephalitis

The Pediatrician’s Role in the Diagnosis and Management of Autistic Spectrum Disorder in Children – PEDIATRICS Vol. 107 No. 5 May 2001

So there is direct evidence that live measles, mumps or rubella viruses separately can cause encephalitis leading to autism.

More troubling is that this has been known for a long time.  So the risks of giving very young children a vaccine containing three live viruses all at once were known. These two World Health Organisation papers published nearly 40 years ago set out the hazards:

Virus-associated immunopathology : animal models and implications for human disease”:

1. Effects of viruses on the immune system, immune-complex diseases, and antibody-mediated immunologic injury Bulletin of The World Health Organisation. 1972; 47(2): 257-264.

2. Cell-mediated immunity, autoimmune diseases, genetics, and implications for clinical research Bulletin of the World Health Organisation. 1972; 47(2): 265-274.

Autistic conditions can result from acute disseminated encephalomyelitis (ADEM) following MMR vaccination as held by the US Federal Court in the case of Bailey Banks.  In his conclusion, US Federal Court Special Master Abell ruled that Petitioners had proven that the MMR had directly caused a brain inflammation illness called acute disseminated encephalomyelitis (ADEM) which, in turn, had caused the autism spectrum disorder PDD-NOS in the child:

The Court found that Bailey’s ADEM was both caused-in-fact and proximately caused by his vaccination. It is well-understood that the vaccination at issue can cause ADEM, and the Court found, based upon a full reading and hearing of the pertinent facts in this case, that it did actually cause the ADEM. Furthermore, Bailey’s ADEM was severe enough to cause lasting, residual damage, and retarded his developmental progress, which fits under the generalized heading of Pervasive Developmental Delay, or PDD [an autism spectrum disorder]. The Court found that Bailey would not have suffered this delay but for the administration of the MMR vaccine, and that this chain of causation was… a proximate sequence of cause and effect leading inexorably from vaccination to Pervasive Developmental Delay.

[Banks v. HHS (Case 02-0738V, 2007 U.S. Claims LEXIS 254, July 20, 2007)].

And what does not cause autism?

Autism is not “caused” by “genes”

Dr Francis S. Collins, M.D., Ph.D. the 16th and current Director of the US$30.5 billion budget National Institutes of Health [nominated by President Obama: NIH News Release 17th August 2009 ] stated in evidence to US House of Representatives Committee May 2006 when Director of the US National Human Genome Research Institute:

Recent increases in chronic diseases like diabetes, childhood asthma, obesity or autism cannot be due to major shifts in the human gene pool as those changes take much more time to occur. They must be due to changes in the environment, including diet and physical activity, which may produce disease in genetically predisposed persons.

Francis S. Collins, M.D., Ph.D. evidence to US House of Representatives Committee May 2006

Collins controls the US $30.5 billion annual medical research budget and is a leading medical doctor and geneticist who led the Human Genome Project.

Autistic conditions affect 1 in 100 US children.  They affect 1 in 64 British children [1 in 40 are boys] according to a Cambridge University study.

ESTIMATING AUTISM SPECTRUM PREVALENCE IN THE POPULATION: A SCHOOL BASED STUDY FROM THE UK

Conclusions: The prevalence estimate of known cases of ASC, using different methods of ascertainment converges around 1%. The ratio of known to unknown cases means that for every three known cases there are another two unknown cases. This has implications for planning diagnostic, social and health services.”

HPV Vaccine Destroys Australian Child’s Ovaries – Manufacturer Didn’t Check

Short link to this page http://wp.me/pfSi7-1Vb

Gardasil Destroys Girl’s Ovaries: Research on Ovaries Never Considered

The BMJ has published the case report of a healthy 16-year-old Australian girl whose womanhood appears to have been stolen by Gardasil vaccinations. She has been thrust into full-fledged menopause, her ovaries irrevocably shut down, before becoming a woman.

The authors, Deirdre Therese Little and Harvey Rodrick Grenville Ward1, draw direct attention to the fact that, though the girl has been thoroughly examined and tested, there is no known explanation other than the series of three Gardasil vaccinations she had. 

[1] Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination, BMJ Reports 2012, Deirdre Therese Little, Harvey Rodrick Grenville Ward, doi:10.1136/bcr-2012-006879

CHS notes as is reported in the nsnbc.com report, the manufacturer provided information to the Australian Therapeutic Goods Administration (TGA) on tests carried out on male rat testes from litters of newborn rats, but not for female rat ovaries.  There is no explanation why the manufacturer omitted this information.  There are likely to be as many female newborns as male in any litter and as the vaccine was to be given to women and girls this missing information is significant.

Additionally, the paper’s authors acknowledge that in 90% of cases the cause is unknown.  The authors draw attention to the fact that whilst it is a rare condition to occur in a teenage girl it is more unusual in a well teenage individual.  Whilst the predominant causes are different in the adolescent the cause is not proven to be the vaccine. However, the number of women with POF is increasing.

Re Posted by CHS.  Original Post: Published July 22, 2013, filed under HEALTH

Read on for more: Gardasil Destroys Girl’s Ovaries: Research on Ovaries Never Considered

________________________________

As Gardasil is the same vaccine given universally to all British 12 year-old schoolgirls since Sept 2012 and to US women and girls CHS is also reposting here the following world exclusive report published only two days ago. [Added July 30 @ 0511GMT / 29 July @2211PDT]

WORLD EXCLUSIVE – UK Drug Safety Agency Falsified Vaccine Safety Data For 6 Million – Millions of Children At Serious Risk

Posted on July 28, 2013 by ChildHealthSafety

Short link to this page: http://wp.me/pfSi7-1UC

This world exclusive report by CHS follows the decision by health authorities in Japan to withdraw their recommendation for human papilloma virus [HPV] vaccines because of high levels of serious adverse reactions in Japanese women and girls.  Japanese girls will still be able to be vaccinated at no charge, but from now on they will be informed by healthcare providers that the health ministry does not recommend the vaccines. 

Cervarix and Gardasil HPV vaccines were found to cause substantially higher rates of adverse reactions than other vaccines: Cervix vaccine issues trigger health notice Japan Times Jun 15, 2013 National Kyodo.

One report claims the rate of serious adverse reactions which Japanese women experienced after Cervarix injections are 52 times the rate of those reported after annual influenza vaccines: Urgent Request from Japan: Help Stop HPV Vaccinations July 27, 2013 By Norma Erickson SaneVax, Inc.

The UK media fail to report this kind of news affecting millions of British school children and families despite affecting their own families and networks of relatives in the UK.  Journalism is a dying profession.  So don’t buy newspapers or believe TV news reports.  The UK’s BBC has become the British Government’s press office.

British Parents Not Told Their Children Are Not At Risk of Cervical Cancer

The targeted vaccination group of 12-year-old British schoolgirls are at no risk of contracting cervical cancer.  Cervical cancer is an extremely rare disease.  The risk is normally zero up to age 20The risk of serious adverse reactions from the vaccine is therefore infinitely higher.  In the UK the disease is so rare there are just 3 deaths in every 100,000 women of all ages as figures from Cancer Research UK showWhat is worse is that by the time there is any risk for these schoolgirls any effect from the vaccine [if there ever was one] would have worn off yet these young women may then think they are protected and fail to undergo routine screening when they will still need it regardless of the vaccine. 

By the time there is any risk of mortality for these 12 year-old schoolgirls it is extremely low.  The risk of death from cervical cancer in the age range 20-24 is 3 in every million women of that age range.  The disease does not normally affect schoolgirls.  The highest number of deaths occur in women in their late seventies.

How UK Health Officials Tampered With the Adverse Reaction Reporting Systems

In the UK the Medicines and Healthcare Products Regulatory Agency [MHRA] first interference was to encourage health professional not to report adverse reactions.  This was done in formal advice issued in the name of Chief Executive Professor Sir Kent Woods telling health professionals that reactions can be “psychogenic” – or in simpler terms a figment of 12 year old schoolgirls’ imaginations and nothing to do with the vaccines [see more below for full details].

Next the data from over 6000 reports of suspected adverse reactions was systematically altered resulting in the MHRA declaring the vaccine safe when it was not. 

The third thing the MHRA staff did was to fix the final figures to make the rate of adverse reactions appear lower by substituting the number of doses given for the number of children receiving the vaccine.  Tampering with statistics by basing rates of adverse reactions on doses given reduced the numbers of adverse reactions per child by three times.  This is because each child was to receive three doses of the vaccine.  So whilst 6 million doses may have been given that represented only around one third of that figure in children receiving the vaccine – resulting in the rates of adverse reactions reported being calculated as 300% lower than they were per child. 

In other words if all children received all three doses then the crucial figure was not the number of doses but the number of children who suffered reactions compared to the total number of children.

The MHRA was headed at the time by Chairman Professor Alasdair Breckenridge [retired December 2012] and Professor Sir Kent Woods [MHRA Chief Executive but shortly expected to retire after 10 years service].

Questions For Heads Of UK Drug Regulatory Agency – MHRA

The first question for Professors Breckenridge and Woods is – if Japanese women suffered adverse reactions at a rate 52 times higher for GSK’s Cervarix vaccine than for flu vaccine how can possible adverse reactions just be figments of childrens’ imagination and so are not to be reported by medical professionals? [“psychogenic” was how Woods put it more formally – see his official advice to medical professionals – more below].

Clearly, that cannot be the case. Not only that but Woods and Breckenridge cannot claim to be ignorant of those facts. They must know that is the position. Nearly half of all reports included what the MHRA categorised as “psychogenic” symptoms which the MHRA say are “all in the mind” and could not therefore be caused by the vaccine.  A full list in a spreadsheet to enable further sorting and analysis can be downloaded here: 130728 Single list of all Cervarix Yellow Card Reports or browsed at the end of this article.  

You can also download the MHRA’s own published .pdf analyses listing the symptoms reported broken up into these five groups.  These are the reports used to declare the vaccine safe:

Here are just a few examples of MHRA’s alleged “all in the mind” “psychogenic” reactions by “hysterical schoolgirls”:

  • convulsions [which are serious reactions with risks of serious brain injury];
  • grand mal convulsions;
  • deafness
  • circulatory collapse;
  • acquired colour blindness;
  • head banging;
  • foaming at mouth;
  • transient blindness;
  • transient deafness;

The next question is: who instructed staff of the UK’s Medicines and Healthcare Products Regulatory Agency [MHRA] systematically to tamper with the reporting systems and with data in reports of adverse reactions by medical professionals to Cervarix HPV vaccines given to millions British Schoolgirls from December 2008 to July 2012?

And the next question is who instructed that none of the adverse reaction reports should be followed-up and conditions of the children investigated?  There is little point having drug safety monitoring if the data obtained from it is ignored.  The MHRA hid the conditions in those cases which were reported.

Official Excuses for Withdrawal of GSK’s Cervarix HPV Vaccine Do Not Stand Up

In 2012 GSK’s Cervarix HPV vaccine was replaced by Merck’s Gardasil HPV vaccine.  At the time this was claimed to be a result of competitive tendering.  However it is a requirement that the Department of Health is required to ensure vaccine supply is not from a sole source.  This requirement was made following criticism in the English Parliament and by the UK National Audit Office over problems caused previously by the failure of a sole source of supply of a different vaccine.

Professor Sir Kent Woods Instructs Medical Professionals Not To Report Adverse Reactions.

In advice dated 2nd September 2008 issued by the UK MHRA in Professor Kent Woods name Professor Woods primed health professionals to expect the most common adverse reactions would be “psychogenic”.  Professor Woods then advised medical professionals not to report an adverse reaction if it “may” be psychogenic. 

“Psychogenic” means that the symptom of the adverse reaction is to be treated as “all in the minds” of the British schoolgirls receiving GSK’s Cervarix vaccine – that is: the result of emotional or mental stress from the administration of the vaccine.

In other words – and feminists please take note – the male dominated MHRA was telling medical professionals to dismiss adverse reactions in schoolgirls because women are prone to that sort of thing – you know – women are silly, emotional and prone to hysteria and mass hysteria.

This advice was not only counterproductive but unscientific and improper from a drug safety perspective.  Professors Woods and Breckenridge must know that. 

Adverse reactions to all pharmaceuticals are heavily under-reported.  Because of that medical professionals are constantly and generally encouraged to file adverse reaction reports to improve drug safety monitoring. Professor Woods’ advice was encouraging them not to.

An adverse reaction reporting system relies on the spectrum of adverse events to be reported so that it is possible to identify the “signal” of a previously unidentified adverse drug reaction against the background of known adverse reactions and reports. 

By encouraging medical professionals to expect and then not to report suspected “psychogenic” reactions would result in reactions which were not psychogenic being identified as such and which would then not be reported following Professor Kent Woods’ advice.  This would also make drug safety monitoring much less effective because if there were truly any “psychogenic” reactions, then subsequent analyses of the data could assist to identify which were likely to have been and which were not so likely or were not.  But the less data one has makes the task more difficult.

MHRA Systematically Tampered with 6000 reports of Adverse Reactions To Declare The Vaccine Safe

From April 2008 up to 31st July 2012, the MHRA received a total of 6213 reports of suspected adverse reactions documenting 14,300 symptoms or 2 1/2 symptoms per report.  Nurses contributed more than two-thirds of all reports.  Over 6 million doses of the vaccine were administered.

The way the reports of suspected adverse reactions to GSK’s Cervarix vaccine were tampered with was to ensure the underlying conditions indicated by the reported symptoms could not be identified.  In addition, no clinical follow-up was carried out on any Cervarix Yellow Card report of a suspected adverse reaction. 

To diagnose an individual it is essential to consider all symptoms suffered by that individual and carry out a clinical assessment on a case-by-case basis.  For example, how do you know if you might have flu?  If you have fever, cough, headache, aching muscles and tiredness then you may have flu.

What the MHRA did was to carry out a paper analysis of the Yellow Card reports.  They separated out the symptoms reported for each individual so that it would be impossible for anyone to identify the underlying conditions each individual suffered.  SOURCE: MHRA 29 July 2010 “Suspected Adverse Reaction Analysis”

Here are the 5 categories each symptom was separated into:

A. Injection-site reactions
B. Allergic reactions
C. ‘Psychogenic’ events
D. ‘Other recognised’ reactions
E. not currently recognised

So if we consider by analogy a disease most people know about, flu, if this approach was applied to infectious disease reports each symptom would be split up and put into one or more of these categories.  As the symptoms are no longer linked together it is impossible to say whether anyone was suffering from ‘flu or any other disease.  There would be no way of telling.

Thus, the MHRA set about hiding the numbers and types of suspected ADRs suffered by British schoolchildren. This was not a conspiracy but fact – that is what the MHRA did.

If this approach were adopted to reporting infectious diseases generally the public could have no idea which diseases are present in the population at any time.  There can be numerous infections diseases circulating simultaneously.

For example, a symptom of encephalitis is headache – in the period Sept 08 to 29 July 2010  information from MHRA recorded that in 4703 Yellow Card reports there were 848 reports  which included headache as one of the reported symptoms and  which might therefore be of encephalitis. A “quick and dirty” analysis of the MHRA data issued at that time shows that of just 5 of the 32 symptoms of encephalitis at least 2300 reports include at least one symptom of encephalitis.

But this is what the MHRA said having carried out no clinical investigation or analysis of any of the Yellow Card reports:-

The four cases of encephalitis reported so far, amongst the number of girls immunised, do not exceed  the numbers normally expected in the absence of vaccination. There is therefore no suggestion at present that the vaccine can cause encephalitis.”

SOURCE: MHRA 29 July 2010 “Suspected Adverse Reaction Analysis“

This shows

  • MHRA only recorded a report as suspected encephalitis if those specific words appear on the Yellow Card report
  • and confirms MHRA did not consider what underlying conditions are indicated by the symptoms reported on the Yellow Cards

Most reports were by school nurses who are likely only to report the symptoms and not diagnose underlying conditions.

School Head Teachers & Governors

It is obvious from these figures that UK parents are obliged under their Children Act 1989 legal duties to refuse consent.  This also puts head teachers and school governors in a remarkable position for putting children at risk by allowing these vaccination programmes to take place on school premises. Under English law they stand legally in “loco parentis” – in the place of the parents whilst children are under their care in school.

School Nurses & Other Medical Professionals.

Obviously medical practitioners bear a heavy duty of disclosure to obtain informed consent but they are not fulfilling it.  Additionally, it is obvious that anyone proposing to have this vaccine needs to be screened for 1) pre-existing medical conditions putting them at risk and 2) risk of adverse reactions based on prior clinical history.  That is not being done.

Properly informed consent is not being obtained – which legally can give rise to claims for “battery” – not simply negligence and easier to prove.

Parents are being told their 13-year-old girls may be given the vaccine even if the parents refuse consent. Girls of this age might be subject to pressure to persuade them even if parents have refused consent. There are reasons why this may not be lawful under “Gillick competence”.

ANNEX I

LIST OF MHRA REPORTED SYMPTOMS OF ADVERSE REACTIONS TO GSK’S CERVARIX HPV VACCINE – Source MHRA “Suspected Adverse Reaction Analysis” 29th July 2010

[Also downloadable as a spreadsheet from here 130728 Single list of all Cervarix Yellow Card Reports]
System Organ Class Category A to E Reported event (Preferred Term)

Number of cases

A. Injection-site reactions Pain in extremity 485

485

A. Injection-site reactions Injection site swelling 113

113

A. Injection-site reactions Oedema peripheral 109

109

A. Injection-site reactions Limb discomfort 106

106

A. Injection-site reactions Hypoaesthesia 105

105

A. Injection-site reactions Injection site erythema 85

85

A. Injection-site reactions Injection site pain 81

81

A. Injection-site reactions Erythema 45

45

A. Injection-site reactions Paraesthesia 37

37

A. Injection-site reactions Skin discolouration 33

33

A. Injection-site reactions Injection site rash 32

32

A. Injection-site reactions Injection site mass 29

29

A. Injection-site reactions Injection site reaction 26

26

A. Injection-site reactions Pain 23

23

A. Injection-site reactions Contusion 21

21

A. Injection-site reactions Musculoskeletal stiffness 21

21

A. Injection-site reactions Peripheral coldness 20

20

A. Injection-site reactions Local reaction 19

19

A. Injection-site reactions Injection site inflammation 18

18

A. Injection-site reactions Injection site warmth 18

18

A. Injection-site reactions Pain in extremity 16

16

A. Injection-site reactions Local swelling 15

15

A. Injection-site reactions Sensation of heaviness 15

15

A. Injection-site reactions Injection site haematoma 12

12

A. Injection-site reactions Injection site pruritus 11

11

A. Injection-site reactions Rash macular 10

10

A. Injection-site reactions Oedema peripheral 9

9

A. Injection-site reactions Feeling cold 8

8

A. Injection-site reactions Injection site induration 8

8

A. Injection-site reactions Injection site nodule 8

8

A. Injection-site reactions Livedo reticularis 8

8

A. Injection-site reactions Swelling 8

8

A. Injection-site reactions Injection site anaesthesia 6

6

A. Injection-site reactions Injection site swelling 6

6

A. Injection-site reactions Muscular weakness 6

6

A. Injection-site reactions Myalgia 6

6

A. Injection-site reactions Neck pain 6

6

A. Injection-site reactions Pain 6

6

A. Injection-site reactions Rash 6

6

A. Injection-site reactions Erythema 5

5

A. Injection-site reactions Feeling hot 5

5

A. Injection-site reactions Injection site erythema 5

5

A. Injection-site reactions Pruritus 5

5

A. Injection-site reactions Cyanosis 4

4

A. Injection-site reactions Feeling abnormal 4

4

A. Injection-site reactions Injection site infection 4

4

A. Injection-site reactions Musculoskeletal stiffness 4

4

A. Injection-site reactions Pallor 4

4

A. Injection-site reactions Sensory disturbance 4

4

A. Injection-site reactions Tenderness 4

4

A. Injection-site reactions Asthenia 3

3

A. Injection-site reactions Feeling hot 3

3

A. Injection-site reactions Inflammation 3

3

A. Injection-site reactions Injection site discharge 3

3

A. Injection-site reactions Injection site discolouration 3

3

A. Injection-site reactions Injection site irritation 3

3

A. Injection-site reactions Injection site reaction 3

3

A. Injection-site reactions Injection site urticaria 3

3

A. Injection-site reactions Injection site vesicles 3

3

A. Injection-site reactions Limb immobilisation 3

3

A. Injection-site reactions Musculoskeletal pain 3

3

A. Injection-site reactions Poor peripheral circulation 3

3

A. Injection-site reactions Sensory loss 3

3

A. Injection-site reactions Skin warm 3

3

A. Injection-site reactions Dry skin 2

2

A. Injection-site reactions Grip strength decreased 2

2

A. Injection-site reactions Hypoaesthesia 2

2

A. Injection-site reactions Injected limb mobility decreased 2

2

A. Injection-site reactions Injection site cellulitis 2

2

A. Injection-site reactions Injection site coldness 2

2

A. Injection-site reactions Injection site discolouration 2

2

A. Injection-site reactions Injection site mass 2

2

A. Injection-site reactions Injection site pain 2

2

A. Injection-site reactions Peripheral coldness 2

2

A. Injection-site reactions Pruritus 2

2

A. Injection-site reactions Sensory loss 2

2

A. Injection-site reactions Skin discolouration 2

2

A. Injection-site reactions Skin reaction 2

2

A. Injection-site reactions Skin reaction 2

2

A. Injection-site reactions Tenderness 2

2

A. Injection-site reactions Blister 1

1

A. Injection-site reactions Complex regional pain syndrome 1

1

A. Injection-site reactions Extensive swelling of vaccinated limb 1

1

A. Injection-site reactions Hyperaesthesia 1

1

A. Injection-site reactions Hyperaesthesia 1

1

A. Injection-site reactions Hypokinesia 1

1

A. Injection-site reactions Hypokinesia 1

1

A. Injection-site reactions Immobile 1

1

A. Injection-site reactions Impetigo 1

1

A. Injection-site reactions Injection site abscess 1

1

A. Injection-site reactions Injection site anaesthesia 1

1

A. Injection-site reactions Injection site coldness 1

1

A. Injection-site reactions Injection site discomfort 1

1

A. Injection-site reactions Injection site haematoma 1

1

A. Injection-site reactions Injection site haemorrhage 1

1

A. Injection-site reactions Injection site haemorrhage 1

1

A. Injection-site reactions Injection site joint movement impairment 1

1

A. Injection-site reactions Injection site joint pain 1

1

A. Injection-site reactions Injection site movement impairment 1

1

A. Injection-site reactions Injection site movement impairment 1

1

A. Injection-site reactions Injection site papule 1

1

A. Injection-site reactions Injection site paraesthesia 1

1

A. Injection-site reactions Injection site rash 1

1

A. Injection-site reactions Injection site scab 1

1

A. Injection-site reactions Joint swelling 1

1

A. Injection-site reactions Limb immobilisation 1

1

A. Injection-site reactions Local reaction 1

1

A. Injection-site reactions Local swelling 1

1

A. Injection-site reactions Lymphoedema 1

1

A. Injection-site reactions Mass 1

1

A. Injection-site reactions Mobility decreased 1

1

A. Injection-site reactions Muscle rigidity 1

1

A. Injection-site reactions Muscle spasms 1

1

A. Injection-site reactions Muscle tightness 1

1

A. Injection-site reactions Musculoskeletal pain 1

1

A. Injection-site reactions Nausea 1

1

A. Injection-site reactions Nodule 1

1

A. Injection-site reactions Pain of skin 1

1

A. Injection-site reactions Paraesthesia 1

1

A. Injection-site reactions Peripheral vascular disorder 1

1

A. Injection-site reactions Rash 1

1

A. Injection-site reactions Rash maculo-papular 1

1

A. Injection-site reactions Rash pruritic 1

1

A. Injection-site reactions Scab 1

1

A. Injection-site reactions Sensation of heaviness 1

1

A. Injection-site reactions Sensation of pressure 1

1

A. Injection-site reactions Tremor 1

1

A. Injection-site reactions Urticaria 1

1

A. Injection-site reactions Urticaria 1

1

B. Allergic reactions Rash 130

130

B. Allergic reactions Urticaria 89

89

B. Allergic reactions Pruritus 60

60

B. Allergic reactions Erythema 47

47

B. Allergic reactions Swelling face 42

42

B. Allergic reactions Anaphylactic reaction 41

41

B. Allergic reactions Dyspnoea 33

33

B. Allergic reactions Rash generalised 31

31

B. Allergic reactions Rash pruritic 31

31

B. Allergic reactions Oedema peripheral 29

29

B. Allergic reactions Lip swelling 26

26

B. Allergic reactions Rash macular 24

24

B. Allergic reactions Dizziness 23

23

B. Allergic reactions Hypersensitivity 22

22

B. Allergic reactions Eye swelling 18

18

B. Allergic reactions Paraesthesia oral 17

17

B. Allergic reactions Malaise 15

15

B. Allergic reactions Throat tightness 14

14

B. Allergic reactions Rash 13

13

B. Allergic reactions Swollen tongue 13

13

B. Allergic reactions Chest discomfort 11

11

B. Allergic reactions Rash erythematous 11

11

B. Allergic reactions Feeling hot 9

9

B. Allergic reactions Flushing 9

9

B. Allergic reactions Pruritus generalised 9

9

B. Allergic reactions Dermatitis allergic 8

8

B. Allergic reactions Pallor 8

8

B. Allergic reactions Pharyngeal oedema 8

8

B. Allergic reactions Urticaria 8

8

B. Allergic reactions Fatigue 7

7

B. Allergic reactions Oropharyngeal pain 7

7

B. Allergic reactions Paraesthesia 7

7

B. Allergic reactions Angioedema 6

6

B. Allergic reactions Dysphagia 6

6

B. Allergic reactions Headache 6

6

B. Allergic reactions Inflammation 6

6

B. Allergic reactions Pyrexia 6

6

B. Allergic reactions Throat irritation 6

6

B. Allergic reactions Blister 5

5

B. Allergic reactions Dyspnoea 5

5

B. Allergic reactions Hyperventilation 5

5

B. Allergic reactions Hypoaesthesia oral 5

5

B. Allergic reactions Vomiting 5

5

B. Allergic reactions Wheezing 5

5

B. Allergic reactions Anaphylactic shock 4

4

B. Allergic reactions Eyelid oedema 4

4

B. Allergic reactions Hypersensitivity 4

4

B. Allergic reactions Hypoaesthesia 4

4

B. Allergic reactions Local swelling 4

4

B. Allergic reactions Nausea 4

4

B. Allergic reactions Pain in extremity 4

4

B. Allergic reactions Dermatitis allergic 3

3

B. Allergic reactions Erythema 3

3

B. Allergic reactions Eye pruritus 3

3

B. Allergic reactions Eyelid oedema 3

3

B. Allergic reactions Hyperhidrosis 3

3

B. Allergic reactions Laryngeal oedema 3

3

B. Allergic reactions Limb discomfort 3

3

B. Allergic reactions Nasopharyngitis 3

3

B. Allergic reactions Ocular hyperaemia 3

3

B. Allergic reactions Pain 3

3

B. Allergic reactions Petechiae 3

3

B. Allergic reactions Rash erythematous 3

3

B. Allergic reactions Rash macular 3

3

B. Allergic reactions Rash maculo-papular 3

3

B. Allergic reactions Rash pruritic 3

3

B. Allergic reactions Skin irritation 3

3

B. Allergic reactions Skin reaction 3

3

B. Allergic reactions Somnolence 3

3

B. Allergic reactions Swelling 3

3

B. Allergic reactions Vision blurred 3

3

B. Allergic reactions Abdominal pain 2

2

B. Allergic reactions Abdominal pain upper 2

2

B. Allergic reactions Anaphylactic reaction 2

2

B. Allergic reactions Blister 2

2

B. Allergic reactions Body temperature increased 2

2

B. Allergic reactions Cold sweat 2

2

B. Allergic reactions Dermatitis contact 2

2

B. Allergic reactions Dizziness 2

2

B. Allergic reactions Face oedema 2

2

B. Allergic reactions Feeling cold 2

2

B. Allergic reactions Heart rate increased 2

2

B. Allergic reactions Heart rate irregular 2

2

B. Allergic reactions Heat rash 2

2

B. Allergic reactions Lip swelling 2

2

B. Allergic reactions Peripheral coldness 2

2

B. Allergic reactions Pharyngeal oedema 2

2

B. Allergic reactions Pruritus 2

2

B. Allergic reactions Rash generalised 2

2

B. Allergic reactions Skin discolouration 2

2

B. Allergic reactions Skin disorder 2

2

B. Allergic reactions Swollen tongue 2

2

B. Allergic reactions Tachycardia 2

2

B. Allergic reactions Type i hypersensitivity 2

2

B. Allergic reactions Anaphylactoid reaction 1

1

B. Allergic reactions Asthenia 1

1

B. Allergic reactions Asthenopia 1

1

B. Allergic reactions Asthma 1

1

B. Allergic reactions Back pain 1

1

B. Allergic reactions Breath sounds abnormal 1

1

B. Allergic reactions Bronchospasm 1

1

B. Allergic reactions Chest pain 1

1

B. Allergic reactions Chills 1

1

B. Allergic reactions Condition aggravated 1

1

B. Allergic reactions Confusional state 1

1

B. Allergic reactions Conjunctival hyperaemia 1

1

B. Allergic reactions Contusion 1

1

B. Allergic reactions Convulsion 1

1

B. Allergic reactions Cough 1

1

B. Allergic reactions Dermatitis 1

1

B. Allergic reactions Dry throat 1

1

B. Allergic reactions Dysphagia 1

1

B. Allergic reactions Eczema 1

1

B. Allergic reactions Eczema 1

1

B. Allergic reactions Eyelid disorder 1

1

B. Allergic reactions Eyes sunken 1

1

B. Allergic reactions Fatigue 1

1

B. Allergic reactions Feeling abnormal 1

1

B. Allergic reactions Feeling hot 1

1

B. Allergic reactions Feeling jittery 1

1

B. Allergic reactions Generalised erythema 1

1

B. Allergic reactions Gingival swelling 1

1

B. Allergic reactions Headache 1

1

B. Allergic reactions Hypersomnia 1

1

B. Allergic reactions Hypertension 1

1

B. Allergic reactions Hypoventilation 1

1

B. Allergic reactions Increased bronchial secretion 1

1

B. Allergic reactions Infusion site swelling 1

1

B. Allergic reactions Laryngeal oedema 1

1

B. Allergic reactions Lethargy 1

1

B. Allergic reactions Lip blister 1

1

B. Allergic reactions Lip ulceration 1

1

B. Allergic reactions Local reaction 1

1

B. Allergic reactions Loss of consciousness 1

1

B. Allergic reactions Migraine 1

1

B. Allergic reactions Muscle tightness 1

1

B. Allergic reactions Musculoskeletal stiffness 1

1

B. Allergic reactions Myalgia 1

1

B. Allergic reactions Mydriasis 1

1

B. Allergic reactions Nausea 1

1

B. Allergic reactions Neck pain 1

1

B. Allergic reactions Oedema mouth 1

1

B. Allergic reactions Oedema mouth 1

1

B. Allergic reactions Oesophageal discomfort 1

1

B. Allergic reactions Oral discomfort 1

1

B. Allergic reactions Oral pain 1

1

B. Allergic reactions Palpitations 1

1

B. Allergic reactions Panic reaction 1

1

B. Allergic reactions Paraesthesia oral 1

1

B. Allergic reactions Periorbital oedema 1

1

B. Allergic reactions Photophobia 1

1

B. Allergic reactions Piloerection 1

1

B. Allergic reactions Pulse absent 1

1

B. Allergic reactions Purpura 1

1

B. Allergic reactions Pyrexia 1

1

B. Allergic reactions Rash follicular 1

1

B. Allergic reactions Rash papular 1

1

B. Allergic reactions Respiratory rate increased 1

1

B. Allergic reactions Sensation of foreign body 1

1

B. Allergic reactions Sneezing 1

1

B. Allergic reactions Somnolence 1

1

B. Allergic reactions Speech disorder 1

1

B. Allergic reactions Stridor 1

1

B. Allergic reactions Swelling 1

1

B. Allergic reactions Swelling face 1

1

B. Allergic reactions Syncope 1

1

B. Allergic reactions Systemic lupus erythematosus rash 1

1

B. Allergic reactions Tenderness 1

1

B. Allergic reactions Thirst 1

1

B. Allergic reactions Throat irritation 1

1

B. Allergic reactions Throat tightness 1

1

B. Allergic reactions Tremor 1

1

B. Allergic reactions Type IV hypersensitivity reaction 1

1

B. Allergic reactions Urticaria pigmentosa 1

1

B. Allergic reactions Visual impairment 1

1

B. Allergic reactions Vomiting 1

1

C. ‘Psychogenic’ events Dizziness 327

327

C. ‘Psychogenic’ events Syncope 296

296

C. ‘Psychogenic’ events Nausea 151

151

C. ‘Psychogenic’ events Headache 109

109

C. ‘Psychogenic’ events Pallor 108

108

C. ‘Psychogenic’ events Vomiting 77

77

C. ‘Psychogenic’ events Malaise 74

74

C. ‘Psychogenic’ events Tremor 61

61

C. ‘Psychogenic’ events Vision blurred 46

46

C. ‘Psychogenic’ events Feeling hot 45

45

C. ‘Psychogenic’ events Flushing 40

40

C. ‘Psychogenic’ events Cold sweat 35

35

C. ‘Psychogenic’ events Syncope 27

27

C. ‘Psychogenic’ events Hyperhidrosis 25

25

C. ‘Psychogenic’ events Presyncope 23

23

C. ‘Psychogenic’ events Hyperventilation 21

21

C. ‘Psychogenic’ events Loss of consciousness 19

19

C. ‘Psychogenic’ events Dyspnoea 18

18

C. ‘Psychogenic’ events Paraesthesia 18

18

C. ‘Psychogenic’ events Chills 17

17

C. ‘Psychogenic’ events Convulsion 17

17

C. ‘Psychogenic’ events Pyrexia 16

16

C. ‘Psychogenic’ events Somnolence 16

16

C. ‘Psychogenic’ events Dizziness 15

15

C. ‘Psychogenic’ events Fatigue 15

15

C. ‘Psychogenic’ events Heart rate increased 14

14

C. ‘Psychogenic’ events Unresponsive to stimuli 14

14

C. ‘Psychogenic’ events Muscle twitching 13

13

C. ‘Psychogenic’ events Rash 13

13

C. ‘Psychogenic’ events Asthenia 12

12

C. ‘Psychogenic’ events Feeling cold 12

12

C. ‘Psychogenic’ events Hypoaesthesia 12

12

C. ‘Psychogenic’ events Panic attack 12

12

C. ‘Psychogenic’ events Chest discomfort 11

11

C. ‘Psychogenic’ events Dyskinesia 11

11

C. ‘Psychogenic’ events Eye rolling 11

11

C. ‘Psychogenic’ events Tachycardia 11

11

C. ‘Psychogenic’ events Tearfulness 11

11

C. ‘Psychogenic’ events Nervousness 10

10

C. ‘Psychogenic’ events Erythema 9

9

C. ‘Psychogenic’ events Headache 9

9

C. ‘Psychogenic’ events Rash macular 9

9

C. ‘Psychogenic’ events Abdominal pain 8

8

C. ‘Psychogenic’ events Chest pain 8

8

C. ‘Psychogenic’ events Peripheral coldness 8

8

C. ‘Psychogenic’ events Abdominal pain upper 7

7

C. ‘Psychogenic’ events Anxiety 7

7

C. ‘Psychogenic’ events Fall 7

7

C. ‘Psychogenic’ events Hypotension 7

7

C. ‘Psychogenic’ events Lethargy 7

7

C. ‘Psychogenic’ events Muscular weakness 7

7

C. ‘Psychogenic’ events Photophobia 7

7

C. ‘Psychogenic’ events Visual impairment 7

7

C. ‘Psychogenic’ events Confusional state 6

6

C. ‘Psychogenic’ events Deafness 6

6

C. ‘Psychogenic’ events Feeling of body temperature change 6

6

C. ‘Psychogenic’ events Muscle rigidity 6

6

C. ‘Psychogenic’ events Musculoskeletal stiffness 6

6

C. ‘Psychogenic’ events Mydriasis 6

6

C. ‘Psychogenic’ events Nasopharyngitis 6

6

C. ‘Psychogenic’ events Throat tightness 6

6

C. ‘Psychogenic’ events Dizziness postural 5

5

C. ‘Psychogenic’ events Dysgeusia 5

5

C. ‘Psychogenic’ events Feeling abnormal 5

5

C. ‘Psychogenic’ events Pallor 5

5

C. ‘Psychogenic’ events Skin discolouration 5

5

C. ‘Psychogenic’ events Urticaria 5

5

C. ‘Psychogenic’ events Abdominal discomfort 4

4

C. ‘Psychogenic’ events Blindness transient 4

4

C. ‘Psychogenic’ events Body temperature increased 4

4

C. ‘Psychogenic’ events Decreased appetite 4

4

C. ‘Psychogenic’ events Hot flush 4

4

C. ‘Psychogenic’ events Migraine 4

4

C. ‘Psychogenic’ events Muscle spasms 4

4

C. ‘Psychogenic’ events Pulse abnormal 4

4

C. ‘Psychogenic’ events Respiratory rate increased 4

4

C. ‘Psychogenic’ events Tinnitus 4

4

C. ‘Psychogenic’ events Urinary incontinence 4

4

C. ‘Psychogenic’ events Vomiting 4

4

C. ‘Psychogenic’ events Abasia 3

3

C. ‘Psychogenic’ events Agitation 3

3

C. ‘Psychogenic’ events Balance disorder 3

3

C. ‘Psychogenic’ events Blindness 3

3

C. ‘Psychogenic’ events Blood pressure decreased 3

3

C. ‘Psychogenic’ events Cyanosis 3

3

C. ‘Psychogenic’ events Disorientation 3

3

C. ‘Psychogenic’ events Disturbance in attention 3

3

C. ‘Psychogenic’ events Dyspnoea 3

3

C. ‘Psychogenic’ events Dysstasia 3

3

C. ‘Psychogenic’ events Emotional disorder 3

3

C. ‘Psychogenic’ events Feeling drunk 3

3

C. ‘Psychogenic’ events Hearing impaired 3

3

C. ‘Psychogenic’ events Heart rate irregular 3

3

C. ‘Psychogenic’ events Hypoventilation 3

3

C. ‘Psychogenic’ events Nausea 3

3

C. ‘Psychogenic’ events Pain 3

3

C. ‘Psychogenic’ events Pain in extremity 3

3

C. ‘Psychogenic’ events Panic reaction 3

3

C. ‘Psychogenic’ events Rash 3

3

C. ‘Psychogenic’ events Sensory loss 3

3

C. ‘Psychogenic’ events Somnolence 3

3

C. ‘Psychogenic’ events Throat irritation 3

3

C. ‘Psychogenic’ events Vertigo 3

3

C. ‘Psychogenic’ events Amnesia 2

2

C. ‘Psychogenic’ events Blood pressure increased 2

2

C. ‘Psychogenic’ events Body temperature decreased 2

2

C. ‘Psychogenic’ events Bradycardia 2

2

C. ‘Psychogenic’ events Circulatory collapse 2

2

C. ‘Psychogenic’ events Colour blindness acquired 2

2

C. ‘Psychogenic’ events Consciousness fluctuating 2

2

C. ‘Psychogenic’ events Diplopia 2

2

C. ‘Psychogenic’ events Dry mouth 2

2

C. ‘Psychogenic’ events Dry throat 2

2

C. ‘Psychogenic’ events Dysarthria 2

2

C. ‘Psychogenic’ events Dysphagia 2

2

C. ‘Psychogenic’ events Emotional distress 2

2

C. ‘Psychogenic’ events Heart rate decreased 2

2

C. ‘Psychogenic’ events Heart rate increased 2

2

C. ‘Psychogenic’ events Hypertension 2

2

C. ‘Psychogenic’ events Hyperventilation 2

2

C. ‘Psychogenic’ events Hypoacusis 2

2

C. ‘Psychogenic’ events Malaise 2

2

C. ‘Psychogenic’ events Muscular weakness 2

2

C. ‘Psychogenic’ events Myalgia 2

2

C. ‘Psychogenic’ events Neck pain 2

2

C. ‘Psychogenic’ events Oropharyngeal pain 2

2

C. ‘Psychogenic’ events Paraesthesia oral 2

2

C. ‘Psychogenic’ events Presyncope 2

2

C. ‘Psychogenic’ events Procedural dizziness 2

2

C. ‘Psychogenic’ events Pruritus 2

2

C. ‘Psychogenic’ events Pulse pressure decreased 2

2

C. ‘Psychogenic’ events Pupil fixed 2

2

C. ‘Psychogenic’ events Rash generalised 2

2

C. ‘Psychogenic’ events Retching 2

2

C. ‘Psychogenic’ events Salivary hypersecretion 2

2

C. ‘Psychogenic’ events Shock 2

2

C. ‘Psychogenic’ events Vision blurred 2

2

C. ‘Psychogenic’ events Abdominal discomfort 1

1

C. ‘Psychogenic’ events Abdominal distension 1

1

C. ‘Psychogenic’ events Abdominal pain 1

1

C. ‘Psychogenic’ events Abnormal behaviour 1

1

C. ‘Psychogenic’ events Altered state of consciousness 1

1

C. ‘Psychogenic’ events Aphasia 1

1

C. ‘Psychogenic’ events Asthenia 1

1

C. ‘Psychogenic’ events Asthma 1

1

C. ‘Psychogenic’ events Back pain 1

1

C. ‘Psychogenic’ events Blindness transient 1

1

C. ‘Psychogenic’ events Blood pressure increased 1

1

C. ‘Psychogenic’ events Blood pressure systolic decreased 1

1

C. ‘Psychogenic’ events Body temperature decreased 1

1

C. ‘Psychogenic’ events Bruxism 1

1

C. ‘Psychogenic’ events Burning sensation 1

1

C. ‘Psychogenic’ events Chills 1

1

C. ‘Psychogenic’ events Condition aggravated 1

1

C. ‘Psychogenic’ events Convulsion 1

1

C. ‘Psychogenic’ events Cough 1

1

C. ‘Psychogenic’ events Deafness transitory 1

1

C. ‘Psychogenic’ events Depressed level of consciousness 1

1

C. ‘Psychogenic’ events Discomfort 1

1

C. ‘Psychogenic’ events Dissociation 1

1

C. ‘Psychogenic’ events Disturbance in attention 1

1

C. ‘Psychogenic’ events Dry mouth 1

1

C. ‘Psychogenic’ events Ear discomfort 1

1

C. ‘Psychogenic’ events Ear pain 1

1

C. ‘Psychogenic’ events Epistaxis 1

1

C. ‘Psychogenic’ events Eye pain 1

1

C. ‘Psychogenic’ events Eyelid oedema 1

1

C. ‘Psychogenic’ events Face injury 1

1

C. ‘Psychogenic’ events Facial spasm 1

1

C. ‘Psychogenic’ events Fatigue 1

1

C. ‘Psychogenic’ events Fear 1

1

C. ‘Psychogenic’ events Feeling of despair 1

1

C. ‘Psychogenic’ events Foaming at mouth 1

1

C. ‘Psychogenic’ events Gait disturbance 1

1

C. ‘Psychogenic’ events Grand mal convulsion 1

1

C. ‘Psychogenic’ events Grip strength decreased 1

1

C. ‘Psychogenic’ events Head banging 1

1

C. ‘Psychogenic’ events Head discomfort 1

1

C. ‘Psychogenic’ events Heart rate irregular 1

1

C. ‘Psychogenic’ events Heat rash 1

1

C. ‘Psychogenic’ events Hemiparesis 1

1

C. ‘Psychogenic’ events Hot flush 1

1

C. ‘Psychogenic’ events Hyperhidrosis 1

1

C. ‘Psychogenic’ events Hypersomnia 1

1

C. ‘Psychogenic’ events Hypoaesthesia 1

1

C. ‘Psychogenic’ events Hypoaesthesia facial 1

1

C. ‘Psychogenic’ events Hypokinesia 1

1

C. ‘Psychogenic’ events Hypotonia 1

1

C. ‘Psychogenic’ events Incontinence 1

1

C. ‘Psychogenic’ events Lip swelling 1

1

C. ‘Psychogenic’ events Livedo reticularis 1

1

C. ‘Psychogenic’ events Migraine 1

1

C. ‘Psychogenic’ events Muscle contracture 1

1

C. ‘Psychogenic’ events Myoclonus 1

1

C. ‘Psychogenic’ events Nervous system disorder 1

1

C. ‘Psychogenic’ events Oral discomfort 1

1

C. ‘Psychogenic’ events Palpitations 1

1

C. ‘Psychogenic’ events Paraesthesia 1

1

C. ‘Psychogenic’ events Peripheral circulatory failure 1

1

C. ‘Psychogenic’ events Pharyngeal oedema 1

1

C. ‘Psychogenic’ events Photophobia 1

1

C. ‘Psychogenic’ events Poor peripheral circulation 1

1

C. ‘Psychogenic’ events Pruritus 1

1

C. ‘Psychogenic’ events Psychomotor hyperactivity 1

1

C. ‘Psychogenic’ events Pyrexia 1

1

C. ‘Psychogenic’ events Respiratory arrest 1

1

C. ‘Psychogenic’ events Respiratory rate decreased 1

1

C. ‘Psychogenic’ events Seizure anoxic 1

1

C. ‘Psychogenic’ events Sensation of heaviness 1

1

C. ‘Psychogenic’ events Sensory loss 1

1

C. ‘Psychogenic’ events Sinus tachycardia 1

1

C. ‘Psychogenic’ events Sleep attacks 1

1

C. ‘Psychogenic’ events Sudden onset of sleep 1

1

C. ‘Psychogenic’ events Tachypnoea 1

1

C. ‘Psychogenic’ events Tremor 1

1

C. ‘Psychogenic’ events Urticaria 1

1

C. ‘Psychogenic’ events Visual impairment 1

1

D. ‘Other recognised’ reactions Nausea 631

631

D. ‘Other recognised’ reactions Headache 629

629

D. ‘Other recognised’ reactions Dizziness 625

625

D. ‘Other recognised’ reactions Vomiting 260

260

D. ‘Other recognised’ reactions Malaise 220

220

D. ‘Other recognised’ reactions Fatigue 216

216

D. ‘Other recognised’ reactions Pyrexia 175

175

D. ‘Other recognised’ reactions Abdominal pain 69

69

D. ‘Other recognised’ reactions Diarrhoea 55

55

D. ‘Other recognised’ reactions Abdominal pain upper 54

54

D. ‘Other recognised’ reactions Myalgia 49

49

D. ‘Other recognised’ reactions Lethargy 48

48

D. ‘Other recognised’ reactions Feeling hot 43

43

D. ‘Other recognised’ reactions Body temperature increased 36

36

D. ‘Other recognised’ reactions Pain 34

34

D. ‘Other recognised’ reactions Headache 30

30

D. ‘Other recognised’ reactions Influenza like illness 28

28

D. ‘Other recognised’ reactions Nausea 28

28

D. ‘Other recognised’ reactions Oropharyngeal pain 28

28

D. ‘Other recognised’ reactions Arthralgia 25

25

D. ‘Other recognised’ reactions Malaise 25

25

D. ‘Other recognised’ reactions Pyrexia 24

24

D. ‘Other recognised’ reactions Pallor 22

22

D. ‘Other recognised’ reactions Somnolence 22

22

D. ‘Other recognised’ reactions Asthenia 21

21

D. ‘Other recognised’ reactions Chills 21

21

D. ‘Other recognised’ reactions Pain in extremity 21

21

D. ‘Other recognised’ reactions Rash 21

21

Musculoskeletal and connective tissue disorders D. ‘Other recognised’ reactions Arthralgia 20

20

D. ‘Other recognised’ reactions Lymphadenopathy 18

18

D. ‘Other recognised’ reactions Vomiting 16

16

D. ‘Other recognised’ reactions Abdominal discomfort 15

15

D. ‘Other recognised’ reactions Dizziness 15

15

D. ‘Other recognised’ reactions Flushing 14

14

D. ‘Other recognised’ reactions Paraesthesia 14

14

D. ‘Other recognised’ reactions Fatigue 12

12

D. ‘Other recognised’ reactions Tremor 12

12

D. ‘Other recognised’ reactions Pruritus 11

11

D. ‘Other recognised’ reactions Decreased appetite 10

10

D. ‘Other recognised’ reactions Abdominal pain 8

8

D. ‘Other recognised’ reactions Neck pain 8

8

D. ‘Other recognised’ reactions Feeling cold 7

7

D. ‘Other recognised’ reactions Back pain 6

6

D. ‘Other recognised’ reactions Cough 6

6

D. ‘Other recognised’ reactions Hyperhidrosis 6

6

D. ‘Other recognised’ reactions Hypoaesthesia 6

6

D. ‘Other recognised’ reactions Lethargy 6

6

D. ‘Other recognised’ reactions Musculoskeletal stiffness 6

6

D. ‘Other recognised’ reactions Nasopharyngitis 6

6

D. ‘Other recognised’ reactions Abdominal pain upper 5

5

D. ‘Other recognised’ reactions Asthenia 4

4

D. ‘Other recognised’ reactions Body temperature increased 4

4

D. ‘Other recognised’ reactions Erythema 4

4

D. ‘Other recognised’ reactions Feeling of body temperature change 4

4

D. ‘Other recognised’ reactions Migraine 4

4

D. ‘Other recognised’ reactions Myalgia 4

4

D. ‘Other recognised’ reactions Nervousness 4

4

D. ‘Other recognised’ reactions Back pain 3

3

D. ‘Other recognised’ reactions Decreased appetite 3

3

D. ‘Other recognised’ reactions Diarrhoea 3

3

D. ‘Other recognised’ reactions Lower respiratory tract infection 3

3

D. ‘Other recognised’ reactions Muscle fatigue 3

3

D. ‘Other recognised’ reactions Muscular weakness 3

3

D. ‘Other recognised’ reactions Rash generalised 3

3

D. ‘Other recognised’ reactions Somnolence 3

3

D. ‘Other recognised’ reactions Cold sweat 2

2

D. ‘Other recognised’ reactions Dizziness postural 2

2

D. ‘Other recognised’ reactions Feeling abnormal 2

2

D. ‘Other recognised’ reactions Gait disturbance 2

2

D. ‘Other recognised’ reactions Head discomfort 2

2

D. ‘Other recognised’ reactions Hot flush 2

2

D. ‘Other recognised’ reactions Influenza like illness 2

2

D. ‘Other recognised’ reactions Joint swelling 2

2

D. ‘Other recognised’ reactions Limb discomfort 2

2

D. ‘Other recognised’ reactions Listless 2

2

D. ‘Other recognised’ reactions Local reaction 2

2

D. ‘Other recognised’ reactions Musculoskeletal stiffness 2

2

D. ‘Other recognised’ reactions Nasal congestion 2

2

D. ‘Other recognised’ reactions Oropharyngeal pain 2

2

D. ‘Other recognised’ reactions Pain 2

2

D. ‘Other recognised’ reactions Pruritus generalised 2

2

D. ‘Other recognised’ reactions Rash macular 2

2

D. ‘Other recognised’ reactions Skin warm 2

2

D. ‘Other recognised’ reactions Throat irritation 2

2

D. ‘Other recognised’ reactions Abdominal pain lower 1

1

D. ‘Other recognised’ reactions Abdominal pain lower 1

1

D. ‘Other recognised’ reactions Arthralgia 1

1

D. ‘Other recognised’ reactions Axillary mass 1

1

D. ‘Other recognised’ reactions Bedridden 1

1

D. ‘Other recognised’ reactions Body temperature 1

1

D. ‘Other recognised’ reactions Body temperature fluctuation 1

1

D. ‘Other recognised’ reactions Body temperature fluctuation 1

1

D. ‘Other recognised’ reactions Cough 1

1

D. ‘Other recognised’ reactions Dyspnoea 1

1

D. ‘Other recognised’ reactions Feeling of body temperature change 1

1

D. ‘Other recognised’ reactions Gastrointestinal disorder 1

1

D. ‘Other recognised’ reactions Generalised erythema 1

1

D. ‘Other recognised’ reactions Groin pain 1

1

D. ‘Other recognised’ reactions Hot flush 1

1

D. ‘Other recognised’ reactions Hypoaesthesia 1

1

D. ‘Other recognised’ reactions Hypotension 1

1

D. ‘Other recognised’ reactions Ill-defined disorder 1

1

D. ‘Other recognised’ reactions Immunisation reaction 1

1

D. ‘Other recognised’ reactions Induration 1

1

D. ‘Other recognised’ reactions Insomnia 1

1

D. ‘Other recognised’ reactions Limb discomfort 1

1

D. ‘Other recognised’ reactions Local reaction 1

1

D. ‘Other recognised’ reactions Local swelling 1

1

D. ‘Other recognised’ reactions Loss of consciousness 1

1

D. ‘Other recognised’ reactions Lymphadenopathy 1

1

D. ‘Other recognised’ reactions Mobility decreased 1

1

D. ‘Other recognised’ reactions Muscle spasms 1

1

D. ‘Other recognised’ reactions Muscle twitching 1

1

D. ‘Other recognised’ reactions Musculoskeletal chest pain 1

1

D. ‘Other recognised’ reactions Musculoskeletal discomfort 1

1

D. ‘Other recognised’ reactions Musculoskeletal discomfort 1

1

D. ‘Other recognised’ reactions Musculoskeletal pain 1

1

D. ‘Other recognised’ reactions Neck pain 1

1

D. ‘Other recognised’ reactions Night sweats 1

1

D. ‘Other recognised’ reactions Pain in extremity 1

1

D. ‘Other recognised’ reactions Peripheral coldness 1

1

D. ‘Other recognised’ reactions Pharyngitis 1

1

D. ‘Other recognised’ reactions Rash erythematous 1

1

D. ‘Other recognised’ reactions Respiratory disorder 1

1

D. ‘Other recognised’ reactions Respiratory tract infection 1

1

D. ‘Other recognised’ reactions Restlessness 1

1

D. ‘Other recognised’ reactions Rhinorrhoea 1

1

D. ‘Other recognised’ reactions Sensation of heaviness 1

1

D. ‘Other recognised’ reactions Sudden onset of sleep 1

1

D. ‘Other recognised’ reactions Swelling 1

1

D. ‘Other recognised’ reactions Swelling face 1

1

D. ‘Other recognised’ reactions Syncope 1

1

D. ‘Other recognised’ reactions Thirst 1

1

D. ‘Other recognised’ reactions Throat tightness 1

1

D. ‘Other recognised’ reactions Upper respiratory tract infection 1

1

D. ‘Other recognised’ reactions Urticaria 1

1

D. ‘Other recognised’ reactions Weight decreased 1

1

Nervous system disorders E. not currently recognised Headache 47

47

Nervous system disorders E. not currently recognised Syncope 35

35

General disorders and administration site conditions E. not currently recognised Influenza like illness 32

32

Nervous system disorders E. not currently recognised Dizziness 29

29

Nervous system disorders E. not currently recognised Hypoaesthesia 29

29

Nervous system disorders E. not currently recognised Convulsion 28

28

Musculoskeletal and connective tissue disorders E. not currently recognised Pain in extremity 27

27

Gastrointestinal disorders E. not currently recognised Nausea 24

24

Nervous system disorders E. not currently recognised Paraesthesia 20

20

Respiratory, thoracic and mediastinal disorders E. not currently recognised Dyspnoea 19

19

Nervous system disorders E. not currently recognised Lethargy 19

19

General disorders and administration site conditions E. not currently recognised Malaise 19

19

Injury, poisoning and procedural complications E. not currently recognised Drug exposure during pregnancy 18

18

General disorders and administration site conditions E. not currently recognised Fatigue 18

18

General disorders and administration site conditions E. not currently recognised Pyrexia 18

18

General disorders and administration site conditions E. not currently recognised Chest pain 17

17

Gastrointestinal disorders E. not currently recognised Vomiting 17

17

Nervous system disorders E. not currently recognised Migraine 16

16

General disorders and administration site conditions E. not currently recognised Pain 16

16

Musculoskeletal and connective tissue disorders E. not currently recognised Back pain 15

15

Nervous system disorders E. not currently recognised Somnolence 14

14

Nervous system disorders E. not currently recognised Tremor 14

14

Nervous system disorders E. not currently recognised Dizziness 12

12

Musculoskeletal and connective tissue disorders E. not currently recognised Muscular weakness 12

12

Pregnancy, puerperium and perinatal conditions E. not currently recognised Abortion spontaneous 11

11

General disorders and administration site conditions E. not currently recognised Asthenia 11

11

Nervous system disorders E. not currently recognised Headache 11

11

Nervous system disorders E. not currently recognised Loss of consciousness 11

11

Gastrointestinal disorders E. not currently recognised Abdominal pain 10

10

Musculoskeletal and connective tissue disorders E. not currently recognised Myalgia 10

10

Respiratory, thoracic and mediastinal disorders E. not currently recognised Oropharyngeal pain 10

10

Reproductive system and breast disorders E. not currently recognised Amenorrhoea 9

9

General disorders and administration site conditions E. not currently recognised Chest discomfort 9

9

Vascular disorders E. not currently recognised Peripheral coldness 9

9

Skin and subcutaneous tissue disorders E. not currently recognised Alopecia 8

8

Respiratory, thoracic and mediastinal disorders E. not currently recognised Cough 8

8

Metabolism and nutrition disorders E. not currently recognised Decreased appetite 8

8

Respiratory, thoracic and mediastinal disorders E. not currently recognised Epistaxis 8

8

General disorders and administration site conditions E. not currently recognised Fatigue 8

8

General disorders and administration site conditions E. not currently recognised Influenza like illness 8

8

Eye disorders E. not currently recognised Vision blurred 8

8

Respiratory, thoracic and mediastinal disorders E. not currently recognised Asthma 7

7

Gastrointestinal disorders E. not currently recognised Diarrhoea 7

7

General disorders and administration site conditions E. not currently recognised Feeling cold 7

7

Nervous system disorders E. not currently recognised Hypoaesthesia 7

7

Skin and subcutaneous tissue disorders E. not currently recognised Hypoaesthesia facial 7

7

Eye disorders E. not currently recognised Photophobia 7

7

Nervous system disorders E. not currently recognised Syncope 7

7

Reproductive system and breast disorders E. not currently recognised Vaginal haemorrhage 7

7

Infections and infestations E. not currently recognised Viral infection 7

7

Eye disorders E. not currently recognised Vision blurred 7

7

Gastrointestinal disorders E. not currently recognised Abdominal pain 6

6

Nervous system disorders E. not currently recognised Dysarthria 6

6

Ear and labyrinth disorders E. not currently recognised Ear pain 6

6

Nervous system disorders E. not currently recognised Epilepsy 6

6

Psychiatric disorders E. not currently recognised Hallucination 6

6

Psychiatric disorders E. not currently recognised Insomnia 6

6

Infections and infestations E. not currently recognised Lower respiratory tract infection 6

6

Musculoskeletal and connective tissue disorders E. not currently recognised Musculoskeletal stiffness 6

6

Musculoskeletal and connective tissue disorders E. not currently recognised Neck pain 6

6

Cardiac disorders E. not currently recognised Palpitations 6

6

Nervous system disorders E. not currently recognised Paraesthesia 6

6

Infections and infestations E. not currently recognised Post viral fatigue syndrome 6

6

Nervous system disorders E. not currently recognised Sensory disturbance 6

6

Eye disorders E. not currently recognised Visual impairment 6

6

General disorders and administration site conditions E. not currently recognised Abasia 5

5

Nervous system disorders E. not currently recognised Dyskinesia 5

5

Nervous system disorders E. not currently recognised Dysstasia 5

5

Skin and subcutaneous tissue disorders E. not currently recognised Eczema 5

5

Skin and subcutaneous tissue disorders E. not currently recognised Erythema multiforme 5

5

Nervous system disorders E. not currently recognised Facial palsy 5

5

Nervous system disorders E. not currently recognised Grand mal convulsion 5

5

Reproductive system and breast disorders E. not currently recognised Menstruation irregular 5

5

General disorders and administration site conditions E. not currently recognised Oedema peripheral 5

5

Vascular disorders E. not currently recognised Pallor 5

5

Musculoskeletal and connective tissue disorders E. not currently recognised Sensation of heaviness 5

5

Investigations E. not currently recognised Weight decreased 5

5

Psychiatric disorders E. not currently recognised Anxiety 4

4

Musculoskeletal and connective tissue disorders E. not currently recognised Arthralgia 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Blister 4

4

Investigations E. not currently recognised Blood glucose increased 4

4

General disorders and administration site conditions E. not currently recognised Chills 4

4

General disorders and administration site conditions E. not currently recognised Chronic fatigue syndrome 4

4

General disorders and administration site conditions E. not currently recognised Condition aggravated 4

4

Psychiatric disorders E. not currently recognised Confusional state 4

4

Injury, poisoning and procedural complications E. not currently recognised Contusion 4

4

Cardiac disorders E. not currently recognised Cyanosis 4

4

Reproductive system and breast disorders E. not currently recognised Dysmenorrhoea 4

4

Nervous system disorders E. not currently recognised Encephalitis 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Erythema 4

4

General disorders and administration site conditions E. not currently recognised Feeling hot 4

4

Nervous system disorders E. not currently recognised Guillain-barre syndrome 4

4

Vascular disorders E. not currently recognised Hypotension 4

4

Nervous system disorders E. not currently recognised Lethargy 4

4

Reproductive system and breast disorders E. not currently recognised Menorrhagia 4

4

Infections and infestations E. not currently recognised Nasopharyngitis 4

4

Gastrointestinal disorders E. not currently recognised Nausea 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Rash 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Rash 4

4

Skin and subcutaneous tissue disorders E. not currently recognised Skin discolouration 4

4

Respiratory, thoracic and mediastinal disorders E. not currently recognised Wheezing 4

4

Surgical and medical procedures E. not currently recognised Abortion induced 3

3

Skin and subcutaneous tissue disorders E. not currently recognised Alopecia 3

3

Nervous system disorders E. not currently recognised Aphonia 3

3

Nervous system disorders E. not currently recognised Convulsion 3

3

Psychiatric disorders E. not currently recognised Disorientation 3

3

Ear and labyrinth disorders E. not currently recognised Ear pain 3

3

Nervous system disorders E. not currently recognised Epilepsy 3

3

General disorders and administration site conditions E. not currently recognised Feeling abnormal 3

3

Nervous system disorders E. not currently recognised Head discomfort 3

3

Nervous system disorders E. not currently recognised Hemiparesis 3

3

Skin and subcutaneous tissue disorders E. not currently recognised Hyperhidrosis 3

3

Infections and infestations E. not currently recognised Infectious mononucleosis 3

3

Pregnancy, puerperium and perinatal conditions E. not currently recognised Live birth 3

3

Reproductive system and breast disorders E. not currently recognised Menstruation delayed 3

3

Gastrointestinal disorders E. not currently recognised Mouth ulceration 3

3

Musculoskeletal and connective tissue disorders E. not currently recognised Muscle twitching 3

3

Eye disorders E. not currently recognised Mydriasis 3

3

Vascular disorders E. not currently recognised Peripheral coldness 3

3

Pregnancy, puerperium and perinatal conditions E. not currently recognised Premature baby 3

3

General disorders and administration site conditions E. not currently recognised Pyrexia 3

3

Nervous system disorders E. not currently recognised Sensory loss 3

3

Psychiatric disorders E. not currently recognised Tearfulness 3

3

Nervous system disorders E. not currently recognised Tremor 3

3

Nervous system disorders E. not currently recognised Unresponsive to stimuli 3

3

Skin and subcutaneous tissue disorders E. not currently recognised Urticaria 3

3

Skin and subcutaneous tissue disorders E. not currently recognised Urticaria chronic 3

3

Nervous system disorders E. not currently recognised Visual field defect 3

3

General disorders and administration site conditions E. not currently recognised Abasia 2

2

Gastrointestinal disorders E. not currently recognised Abdominal pain upper 2

2

Psychiatric disorders E. not currently recognised Abnormal behaviour 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Alopecia areata 2

2

Reproductive system and breast disorders E. not currently recognised Amenorrhoea 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Angioedema 2

2

Nervous system disorders E. not currently recognised Balance disorder 2

2

Investigations E. not currently recognised Body temperature increased 2

2

Vascular disorders E. not currently recognised Circulatory collapse 2

2

Nervous system disorders E. not currently recognised Complex regional pain syndrome 2

2

Nervous system disorders E. not currently recognised Complex regional pain syndrome 2

2

Psychiatric disorders E. not currently recognised Confusional state 2

2

Nervous system disorders E. not currently recognised Crying 2

2

Metabolism and nutrition disorders E. not currently recognised Dehydration 2

2

Psychiatric disorders E. not currently recognised Depressed mood 2

2

Nervous system disorders E. not currently recognised Diplegia 2

2

Eye disorders E. not currently recognised Diplopia 2

2

Nervous system disorders E. not currently recognised Disturbance in attention 2

2

Nervous system disorders E. not currently recognised Dizziness postural 2

2

Nervous system disorders E. not currently recognised Drooling 2

2

Injury, poisoning and procedural complications E. not currently recognised Drug exposure before pregnancy 2

2

Nervous system disorders E. not currently recognised Dysgeusia 2

2

Psychiatric disorders E. not currently recognised Emotional disorder 2

2

Eye disorders E. not currently recognised Eye pain 2

2

Nervous system disorders E. not currently recognised Facial paresis 2

2

General disorders and administration site conditions E. not currently recognised Feeling cold 2

2

General disorders and administration site conditions E. not currently recognised Gait disturbance 2

2

General disorders and administration site conditions E. not currently recognised Gait disturbance 2

2

Nervous system disorders E. not currently recognised Grand mal convulsion 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Groin pain 2

2

Respiratory, thoracic and mediastinal disorders E. not currently recognised Haemoptysis 2

2

Vascular disorders E. not currently recognised Haemorrhage 2

2

Infections and infestations E. not currently recognised Herpes zoster 2

2

Infections and infestations E. not currently recognised Hordeolum 2

2

Vascular disorders E. not currently recognised Hot flush 2

2

Respiratory, thoracic and mediastinal disorders E. not currently recognised Hyperventilation 2

2

Nervous system disorders E. not currently recognised Hypokinesia 2

2

Infections and infestations E. not currently recognised Influenza 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Joint swelling 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Livedo reticularis 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Livedo reticularis 2

2

General disorders and administration site conditions E. not currently recognised Local swelling 2

2

Nervous system disorders E. not currently recognised Loss of consciousness 2

2

General disorders and administration site conditions E. not currently recognised Malaise 2

2

Reproductive system and breast disorders E. not currently recognised Menstrual disorder 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Mobility decreased 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Muscle spasms 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Muscular weakness 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Musculoskeletal pain 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Musculoskeletal stiffness 2

2

Nervous system disorders E. not currently recognised Optic neuritis 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Pain in extremity 2

2

Vascular disorders E. not currently recognised Pallor 2

2

Gastrointestinal disorders E. not currently recognised Paraesthesia oral 2

2

Nervous system disorders E. not currently recognised Petit mal epilepsy 2

2

Infections and infestations E. not currently recognised Pharyngitis 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Photosensitivity reaction 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Photosensitivity reaction 2

2

Congenital, familial and genetic disorders E. not currently recognised Pilonidal cyst congenital 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Purpura 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Rash generalised 2

2

Musculoskeletal and connective tissue disorders E. not currently recognised Rheumatoid arthritis 2

2

Respiratory, thoracic and mediastinal disorders E. not currently recognised Rhinorrhoea 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Skin exfoliation 2

2

Psychiatric disorders E. not currently recognised Sleep disorder 2

2

Skin and subcutaneous tissue disorders E. not currently recognised Swelling face 2

2

Cardiac disorders E. not currently recognised Tachycardia 2

2

Renal and urinary disorders E. not currently recognised Urinary incontinence 2

2

Renal and urinary disorders E. not currently recognised Urinary retention 2

2

Infections and infestations E. not currently recognised Urinary tract infection 2

2

Ear and labyrinth disorders E. not currently recognised Vertigo 2

2

Eye disorders E. not currently recognised Visual impairment 2

2

Reproductive system and breast disorders E. not currently recognised Vulval ulceration 2

2

Investigations E. not currently recognised Weight increased 2

2

Gastrointestinal disorders E. not currently recognised Abdominal discomfort 1

1

Gastrointestinal disorders E. not currently recognised Abdominal discomfort 1

1

Gastrointestinal disorders E. not currently recognised Abdominal pain lower 1

1

Gastrointestinal disorders E. not currently recognised Abdominal pain upper 1

1

Gastrointestinal disorders E. not currently recognised Abnormal faeces 1

1

Psychiatric disorders E. not currently recognised Abnormal sleep-related event 1

1

Infections and infestations E. not currently recognised Abscess 1

1

Infections and infestations E. not currently recognised Acarodermatitis 1

1

Eye disorders E. not currently recognised Accommodation disorder 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Acne 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Acne 1

1

Neoplasms benign, malignant and unspecified (incl cysts and polyps) E. not currently recognised Acute myeloid leukaemia 1

1

Psychiatric disorders E. not currently recognised Acute psychosis 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Acute respiratory failure 1

1

Endocrine disorders E. not currently recognised Adrenocortical insufficiency acute 1

1

Endocrine disorders E. not currently recognised Adrenocortical insufficiency acute 1

1

Psychiatric disorders E. not currently recognised Aggression 1

1

Investigations E. not currently recognised Alanine aminotransferase increased 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Alopecia areata 1

1

Blood and lymphatic system disorders E. not currently recognised Anaemia 1

1

Infections and infestations E. not currently recognised Anogenital warts 1

1

Nervous system disorders E. not currently recognised Aphasia 1

1

Blood and lymphatic system disorders E. not currently recognised Aplastic anaemia 1

1

Infections and infestations E. not currently recognised Application site pustules 1

1

Nervous system disorders E. not currently recognised Areflexia 1

1

Congenital, familial and genetic disorders E. not currently recognised Arteriovenous malformation 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Arthritis 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Arthritis reactive 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Arthropathy 1

1

General disorders and administration site conditions E. not currently recognised Asthenia 1

1

Nervous system disorders E. not currently recognised Ataxia 1

1

Injury, poisoning and procedural complications E. not currently recognised Axillary nerve injury 1

1

General disorders and administration site conditions E. not currently recognised Axillary pain 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Back pain 1

1

Nervous system disorders E. not currently recognised Balance disorder 1

1

Neoplasms benign, malignant and unspecified (incl cysts and polyps) E. not currently recognised Benign hydatidiform mole 1

1

Infections and infestations E. not currently recognised Beta haemolytic streptococcal infection 1

1

Eye disorders E. not currently recognised Blindness unilateral 1

1

Investigations E. not currently recognised Blood cortisol decreased 1

1

Investigations E. not currently recognised Blood pressure decreased 1

1

Investigations E. not currently recognised Blood pressure increased 1

1

Investigations E. not currently recognised Body temperature increased 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Bone pain 1

1

Reproductive system and breast disorders E. not currently recognised Breast pain 1

1

Reproductive system and breast disorders E. not currently recognised Breast swelling 1

1

Reproductive system and breast disorders E. not currently recognised Breast tenderness 1

1

Infections and infestations E. not currently recognised Bronchitis 1

1

Nervous system disorders E. not currently recognised Burning sensation 1

1

Cardiac disorders E. not currently recognised Cardiac arrest 1

1

Investigations E. not currently recognised Cell marker increased 1

1

Congenital, familial and genetic disorders E. not currently recognised Cerebral palsy 1

1

Reproductive system and breast disorders E. not currently recognised Cervix inflammation 1

1

General disorders and administration site conditions E. not currently recognised Chest discomfort 1

1

General disorders and administration site conditions E. not currently recognised Chest pain 1

1

General disorders and administration site conditions E. not currently recognised Chills 1

1

Nervous system disorders E. not currently recognised Chorea 1

1

Congenital, familial and genetic disorders E. not currently recognised Cleft palate 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Cold sweat 1

1

Gastrointestinal disorders E. not currently recognised Colitis 1

1

Gastrointestinal disorders E. not currently recognised Colitis ulcerative 1

1

General disorders and administration site conditions E. not currently recognised Condition aggravated 1

1

Eye disorders E. not currently recognised Conjunctival hyperaemia 1

1

Gastrointestinal disorders E. not currently recognised Constipation 1

1

Nervous system disorders E. not currently recognised Coordination abnormal 1

1

Investigations E. not currently recognised Csf cell count increased 1

1

Eye disorders E. not currently recognised Dark circles under eyes 1

1

Ear and labyrinth disorders E. not currently recognised Deafness 1

1

Ear and labyrinth disorders E. not currently recognised Deafness bilateral 1

1

Metabolism and nutrition disorders E. not currently recognised Decreased appetite 1

1

Psychiatric disorders E. not currently recognised Decreased interest 1

1

Vascular disorders E. not currently recognised Deep vein thrombosis 1

1

Nervous system disorders E. not currently recognised Depressed level of consciousness 1

1

Psychiatric disorders E. not currently recognised Depression 1

1

Psychiatric disorders E. not currently recognised Depression 1

1

Psychiatric disorders E. not currently recognised Depressive symptom 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Dermatitis allergic 1

1

Metabolism and nutrition disorders E. not currently recognised Diabetes mellitus inadequate control 1

1

Metabolism and nutrition disorders E. not currently recognised Diabetes mellitus inadequate control 1

1

Metabolism and nutrition disorders E. not currently recognised Diabetic ketoacidosis 1

1

Gastrointestinal disorders E. not currently recognised Diarrhoea 1

1

Gastrointestinal disorders E. not currently recognised Diarrhoea haemorrhagic 1

1

General disorders and administration site conditions E. not currently recognised Discomfort 1

1

Psychiatric disorders E. not currently recognised Dissociation 1

1

Nervous system disorders E. not currently recognised Dizziness postural 1

1

Eye disorders E. not currently recognised Dry eye 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Dry skin 1

1

Nervous system disorders E. not currently recognised Dysgeusia 1

1

Nervous system disorders E. not currently recognised Dyskinesia 1

1

Psychiatric disorders E. not currently recognised Dysphemia 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Dyspnoea 1

1

Ear and labyrinth disorders E. not currently recognised Ear discomfort 1

1

Psychiatric disorders E. not currently recognised Eating disorder 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Eczema vesicular 1

1

Psychiatric disorders E. not currently recognised Emotional distress 1

1

Nervous system disorders E. not currently recognised Encephalitis 1

1

Blood and lymphatic system disorders E. not currently recognised Eosinophilia 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Erythema 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Erythema multiforme 1

1

Eye disorders E. not currently recognised Excessive eye blinking 1

1

General disorders and administration site conditions E. not currently recognised Exercise tolerance decreased 1

1

Eye disorders E. not currently recognised Eye discharge 1

1

Eye disorders E. not currently recognised Eye disorder 1

1

Eye disorders E. not currently recognised Eye pain 1

1

Eye disorders E. not currently recognised Eye swelling 1

1

Eye disorders E. not currently recognised Eyelid oedema 1

1

Nervous system disorders E. not currently recognised Facial palsy 1

1

Injury, poisoning and procedural complications E. not currently recognised Fall 1

1

Psychiatric disorders E. not currently recognised Fear 1

1

General disorders and administration site conditions E. not currently recognised Feeling abnormal 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Flank pain 1

1

Gastrointestinal disorders E. not currently recognised Flatulence 1

1

Vascular disorders E. not currently recognised Flushing 1

1

Infections and infestations E. not currently recognised Folliculitis 1

1

Gastrointestinal disorders E. not currently recognised Frequent bowel movements 1

1

Infections and infestations E. not currently recognised Furuncle 1

1

Gastrointestinal disorders E. not currently recognised Gastrointestinal disorder 1

1

Eye disorders E. not currently recognised Gaze palsy 1

1

Gastrointestinal disorders E. not currently recognised Gingival disorder 1

1

Nervous system disorders E. not currently recognised Guillain-barre syndrome 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Guttate psoriasis 1

1

Blood and lymphatic system disorders E. not currently recognised Haemolytic uraemic syndrome 1

1

Psychiatric disorders E. not currently recognised Hallucination, auditory 1

1

Psychiatric disorders E. not currently recognised Hallucination, visual 1

1

Congenital, familial and genetic disorders E. not currently recognised Heart disease congenital 1

1

Investigations E. not currently recognised Heart rate decreased 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Henoch-schonlein purpura 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Henoch-schonlein purpura 1

1

Infections and infestations E. not currently recognised Hepatitis viral 1

1

Infections and infestations E. not currently recognised Herpes zoster 1

1

Ear and labyrinth disorders E. not currently recognised Hyperacusis 1

1

Metabolism and nutrition disorders E. not currently recognised Hyperglycaemia 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Hyperhidrosis 1

1

General disorders and administration site conditions E. not currently recognised Hyperpyrexia 1

1

Immune system disorders E. not currently recognised Hypersensitivity 1

1

Nervous system disorders E. not currently recognised Hypertonia 1

1

Ear and labyrinth disorders E. not currently recognised Hypoacusis 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Hypoaesthesia facial 1

1

Gastrointestinal disorders E. not currently recognised Hypoaesthesia oral 1

1

Metabolism and nutrition disorders E. not currently recognised Hypoglycaemia 1

1

Psychiatric disorders E. not currently recognised Hypomania 1

1

Congenital, familial and genetic disorders E. not currently recognised Hypospadias 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Hypoventilation 1

1

Injury, poisoning and procedural complications E. not currently recognised Inappropriate schedule of drug administration 1

1

Injury, poisoning and procedural complications E. not currently recognised Incorrect dose administered 1

1

Metabolism and nutrition disorders E. not currently recognised Increased appetite 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Increased upper airway secretion 1

1

Infections and infestations E. not currently recognised Infection 1

1

General disorders and administration site conditions E. not currently recognised Inflammation 1

1

General disorders and administration site conditions E. not currently recognised Injection site erythema 1

1

General disorders and administration site conditions E. not currently recognised Injection site injury 1

1

General disorders and administration site conditions E. not currently recognised Injection site swelling 1

1

Psychiatric disorders E. not currently recognised Insomnia 1

1

Gastrointestinal disorders E. not currently recognised Intestinal functional disorder 1

1

Gastrointestinal disorders E. not currently recognised Irritable bowel syndrome 1

1

Nervous system disorders E. not currently recognised Ivth nerve paralysis 1

1

Hepatobiliary disorders E. not currently recognised Jaundice 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Joint stiffness 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Joint stiffness 1

1

Infections and infestations E. not currently recognised Kidney infection 1

1

Infections and infestations E. not currently recognised Labyrinthitis 1

1

Infections and infestations E. not currently recognised Laryngitis 1

1

Congenital, familial and genetic disorders E. not currently recognised Limb malformation 1

1

Gastrointestinal disorders E. not currently recognised Lip blister 1

1

Gastrointestinal disorders E. not currently recognised Lip swelling 1

1

General disorders and administration site conditions E. not currently recognised Local swelling 1

1

Nervous system disorders E. not currently recognised Meningism 1

1

Reproductive system and breast disorders E. not currently recognised Menorrhagia 1

1

Reproductive system and breast disorders E. not currently recognised Menstrual disorder 1

1

Reproductive system and breast disorders E. not currently recognised Menstruation delayed 1

1

Reproductive system and breast disorders E. not currently recognised Menstruation irregular 1

1

Reproductive system and breast disorders E. not currently recognised Metrorrhagia 1

1

Nervous system disorders E. not currently recognised Migraine 1

1

Nervous system disorders E. not currently recognised Migraine with aura 1

1

Infections and infestations E. not currently recognised Molluscum contagiosum 1

1

Nervous system disorders E. not currently recognised Monoplegia 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Muscle rigidity 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Muscle twitching 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Musculoskeletal chest pain 1

1

Nervous system disorders E. not currently recognised Myoclonic epilepsy 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Nasal congestion 1

1

Neoplasms benign, malignant and unspecified (incl cysts and polyps) E. not currently recognised Neoplasm malignant 1

1

Nervous system disorders E. not currently recognised Neuritis 1

1

Renal and urinary disorders E. not currently recognised Neurogenic bladder 1

1

Blood and lymphatic system disorders E. not currently recognised Neutropenia 1

1

Investigations E. not currently recognised Neutrophil count decreased 1

1

General disorders and administration site conditions E. not currently recognised Oedema peripheral 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Oropharyngeal blistering 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Oropharyngeal pain 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Osteitis 1

1

Infections and infestations E. not currently recognised Otitis media 1

1

General disorders and administration site conditions E. not currently recognised Pain 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Palindromic rheumatism 1

1

Blood and lymphatic system disorders E. not currently recognised Pancytopenia 1

1

Nervous system disorders E. not currently recognised Paralysis 1

1

Psychiatric disorders E. not currently recognised Paranoia 1

1

Investigations E. not currently recognised Peak expiratory flow rate decreased 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Petechiae 1

1

Eye disorders E. not currently recognised Photopsia 1

1

Investigations E. not currently recognised Platelet count decreased 1

1

Infections and infestations E. not currently recognised Pneumonia viral 1

1

Renal and urinary disorders E. not currently recognised Pollakiuria 1

1

Pregnancy, puerperium and perinatal conditions E. not currently recognised Pregnancy with injectable contraceptive 1

1

Nervous system disorders E. not currently recognised Presyncope 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Productive cough 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Psoriasis 1

1

Psychiatric disorders E. not currently recognised Psychiatric symptom 1

1

Nervous system disorders E. not currently recognised Psychomotor hyperactivity 1

1

Psychiatric disorders E. not currently recognised Psychotic disorder 1

1

Investigations E. not currently recognised Radial pulse 1

1

Nervous system disorders E. not currently recognised Radiculitis brachial 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Rash erythematous 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Rash maculo-papular 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Rash vesicular 1

1

Renal and urinary disorders E. not currently recognised Renal failure 1

1

Investigations E. not currently recognised Respiratory rate increased 1

1

Infections and infestations E. not currently recognised Respiratory syncytial virus infection 1

1

Infections and infestations E. not currently recognised Respiratory tract infection 1

1

Psychiatric disorders E. not currently recognised Screaming 1

1

Nervous system disorders E. not currently recognised Sedation 1

1

General disorders and administration site conditions E. not currently recognised Sensation of foreign body 1

1

General disorders and administration site conditions E. not currently recognised Sensation of pressure 1

1

Nervous system disorders E. not currently recognised Sensory loss 1

1

Infections and infestations E. not currently recognised Sepsis 1

1

Infections and infestations E. not currently recognised Severe acute respiratory syndrome 1

1

Cardiac disorders E. not currently recognised Sinus tachycardia 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin burning sensation 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin disorder 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin hypertrophy 1

1

Infections and infestations E. not currently recognised Skin infection 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin irritation 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Skin lesion 1

1

Psychiatric disorders E. not currently recognised Somatisation disorder 1

1

Nervous system disorders E. not currently recognised Somnolence 1

1

Nervous system disorders E. not currently recognised Speech disorder 1

1

Infections and infestations E. not currently recognised Staphylococcal infection 1

1

Nervous system disorders E. not currently recognised Status epilepticus 1

1

Infections and infestations E. not currently recognised Streptococcal sepsis 1

1

General disorders and administration site conditions E. not currently recognised Swelling 1

1

Gastrointestinal disorders E. not currently recognised Swollen tongue 1

1

General disorders and administration site conditions E. not currently recognised Systemic inflammatory response syndrome 1

1

General disorders and administration site conditions E. not currently recognised Temperature intolerance 1

1

General disorders and administration site conditions E. not currently recognised Tenderness 1

1

General disorders and administration site conditions E. not currently recognised Thirst 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Throat tightness 1

1

Ear and labyrinth disorders E. not currently recognised Tinnitus 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Trichorrhexis 1

1

Metabolism and nutrition disorders E. not currently recognised Type 1 diabetes mellitus 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Upper airway obstruction 1

1

Infections and infestations E. not currently recognised Upper respiratory tract infection 1

1

Renal and urinary disorders E. not currently recognised Urinary retention 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Urticaria 1

1

Reproductive system and breast disorders E. not currently recognised Vaginal discharge 1

1

Reproductive system and breast disorders E. not currently recognised Vaginal lesion 1

1

Infections and infestations E. not currently recognised Varicella 1

1

Infections and infestations E. not currently recognised Viraemia 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Vitiligo 1

1

Eye disorders E. not currently recognised Vitreous floaters 1

1

Gastrointestinal disorders E. not currently recognised Vomiting 1

1

Musculoskeletal and connective tissue disorders E. not currently recognised Weight bearing difficulty 1

1

Investigations E. not currently recognised Weight decreased 1

1

Respiratory, thoracic and mediastinal disorders E. not currently recognised Wheezing 1

1

Injury, poisoning and procedural complications E. not currently recognised Wrong technique in drug usage process 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Yellow skin 1

1

Skin and subcutaneous tissue disorders E. not currently recognised Stevens-johnson syndrome 1

UK Drug Safety Agency Falsified Vaccine Safety Data For 6 Million

Short link to this page: http://wp.me/pfSi7-1UC

[See also “Japan’s Suspension of Recommendation for Gardasil & Cervarix HPV Vaccines for Women – Caused by Large Numbers of Unexplained Serious Adverse Reactions“]

This world exclusive report by CHS follows the decision by health authorities in Japan to withdraw their recommendation for human papilloma virus [HPV] vaccines because of high levels of serious adverse reactions in Japanese women and girls. 

But in the UK data from over 6000 reports of suspected adverse reactions in British schoolgirls was systematically altered resulting in the Medicines and Healthcare Products Regulatory Agency [MHRA] declaring the vaccine safe when it was not.   With 6 million doses given to nearly 2 million British schoolgirls the MHRA’s actions are serious but benefit British Cervarix vaccine maker GlaxoSmithKline. 98 in 100 adverse drug reactions go unreported: Spontaneous adverse drug reaction reporting vs event monitoring: a comparison: Journal of the Royal Society of Medicine Volume 84 June 1991 341.

In Japan Cervarix and Gardasil HPV vaccines were found to cause substantially higher rates of adverse reactions than other vaccines: Cervix vaccine issues trigger health notice Japan Times Jun 15, 2013 National Kyodo.

One report claims the rate of serious adverse reactions which Japanese women experienced after Cervarix injections are 52 times the rate of those reported after annual influenza vaccines: Urgent Request from Japan: Help Stop HPV Vaccinations July 27, 2013 By Norma Erickson SaneVax, IncJapanese girls will still be able to be vaccinated at no charge, but from now on they will be informed by healthcare providers that the health ministry does not recommend the vaccines.

The UK media fail to report this kind of news affecting millions of British school children and families despite affecting their own families and networks of relatives in the UK.  Journalism is a dying profession.  Don’t buy newspapers or believe TV news reports.  The UK’s BBC has become the British Government’s press office.

British Parents Not Told Their Children Are Not At Risk of Cervical Cancer

The targeted vaccination group of 12-year-old British schoolgirls are at no risk of contracting cervical cancer.  Cervical cancer is an extremely rare disease.  The risk is normally zero up to age 20The risk of serious adverse reactions from the vaccine is therefore infinitely higher.  In the UK the disease is so rare there are just 3 deaths in every 100,000 women of all ages as figures from Cancer Research UK showWhat is worse is that by the time there is any risk for these schoolgirls any effect from the vaccine [if there ever was one] would have worn off yet these young women may then think they are protected and fail to undergo routine screening when they will still need it regardless of the vaccine. 

By the time there is any risk of mortality for these 12 year-old schoolgirls it is extremely low.  The risk of death from cervical cancer in the age range 20-24 is 3 in every million women of that age range.  The disease does not normally affect schoolgirls.  The highest number of deaths occur in women in their late seventies.

How UK Health Officials Tampered With the Adverse Reaction Reporting Systems

In the UK the MHRA’s first interference was to encourage health professional not to report adverse reactions.  This was done in formal advice issued in the name of Chief Executive Professor Sir Kent Woods telling health professionals that reactions can be “psychogenic” – or in simpler terms a figment of 12 year old schoolgirls’ imaginations and nothing to do with the vaccines [see more below for full details].

Next the data from over 6000 reports of suspected adverse reactions was systematically altered resulting in the MHRA declaring the vaccine safe when it was not. 

The third thing the MHRA staff did was to fix the final figures to make the rate of adverse reactions appear lower by substituting the number of doses given for the number of children receiving the vaccine.  Tampering with statistics by basing rates of adverse reactions on doses given reduced the numbers of adverse reactions per child by three times.  This is because each child was to receive three doses of the vaccine.  So whilst 6 million doses may have been given that represented only around one third of that figure in children receiving the vaccine – resulting in the rates of adverse reactions reported being calculated as 300% lower than they were per child. 

In other words if all children received all three doses then the crucial figure was not the number of doses but the number of children who suffered reactions compared to the total number of children.

The MHRA was headed at the time by Chairman Professor Alasdair Breckenridge [retired December 2012] and Professor Sir Kent Woods [MHRA Chief Executive but shortly expected to retire after 10 years service].

Questions For Heads Of UK Drug Regulatory Agency – MHRA

The first question for Professors Breckenridge and Woods is – if Japanese women suffered adverse reactions at a rate 52 times higher for GSK’s Cervarix vaccine than for flu vaccine how can possible adverse reactions just be figments of childrens’ imagination and so are not to be reported by medical professionals? [“psychogenic” was how Woods put it more formally – see his official advice to medical professionals – more below].

Clearly, that cannot be the case. Not only that but Woods and Breckenridge cannot claim to be ignorant of those facts. They must know that is the position. Nearly half of all reports included what the MHRA categorised as “psychogenic” symptoms which the MHRA say are “all in the mind” and could not therefore be caused by the vaccine.  A full list in a spreadsheet to enable further sorting and analysis can be downloaded here: 130728 Single list of all Cervarix Yellow Card Reports or browsed at the end of this article.  

You can also download the MHRA’s own published .pdf analyses listing the symptoms reported broken up into these five groups.  These are the reports used to declare the vaccine safe:

Here are just a few examples of MHRA’s alleged “all in the mind” “psychogenic” reactions by “hysterical schoolgirls”:

  • convulsions [which are serious reactions with risks of serious brain injury];
  • grand mal convulsions;
  • deafness
  • circulatory collapse;
  • acquired colour blindness;
  • head banging;
  • foaming at mouth;
  • transient blindness;
  • transient deafness;

The next question is: who instructed staff of the UK’s Medicines and Healthcare Products Regulatory Agency [MHRA] systematically to tamper with the reporting systems and with data in reports of adverse reactions by medical professionals to Cervarix HPV vaccines given to millions British Schoolgirls from December 2008 to July 2012?

And the next question is who instructed that none of the adverse reaction reports should be followed-up and conditions of the children investigated?  There is little point having drug safety monitoring if the data obtained from it is ignored.  The MHRA hid the conditions in those cases which were reported.

Official Excuses for Withdrawal of GSK’s Cervarix HPV Vaccine Do Not Stand Up

In 2012 GSK’s Cervarix HPV vaccine was replaced by Merck’s Gardasil HPV vaccine.  At the time this was claimed to be a result of competitive tendering.  However it is a requirement that the Department of Health is required to ensure vaccine supply is not from a sole source.  This requirement was made following criticism in the English Parliament and by the UK National Audit Office over problems caused previously by the failure of a sole source of supply of a different vaccine.

Professor Sir Kent Woods Instructs Medical Professionals Not To Report Adverse Reactions.

In advice dated 2nd September 2008 issued by the UK MHRA in Professor Kent Woods name Professor Woods primed health professionals to expect the most common adverse reactions would be “psychogenic”.  Professor Woods then advised medical professionals not to report an adverse reaction if it “may” be psychogenic. 

“Psychogenic” means that the symptom of the adverse reaction is to be treated as “all in the minds” of the British schoolgirls receiving GSK’s Cervarix vaccine – that is: the result of emotional or mental stress from the administration of the vaccine.

In other words – and feminists please take note – the male dominated MHRA was telling medical professionals to dismiss adverse reactions in schoolgirls because women are prone to that sort of thing – you know – women are silly, emotional and prone to hysteria and mass hysteria.

This advice was not only counterproductive but unscientific and improper from a drug safety perspective.  Professors Woods and Breckenridge must know that. 

Adverse reactions to all pharmaceuticals are heavily under-reported.  Because of that medical professionals are constantly and generally encouraged to file adverse reaction reports to improve drug safety monitoring. Professor Woods’ advice was encouraging them not to.

An adverse reaction reporting system relies on the spectrum of adverse events to be reported so that it is possible to identify the “signal” of a previously unidentified adverse drug reaction against the background of known adverse reactions and reports. 

By encouraging medical professionals to expect and then not to report suspected “psychogenic” reactions would result in reactions which were not psychogenic being identified as such and which would then not be reported following Professor Kent Woods’ advice.  This would also make drug safety monitoring much less effective because if there were truly any “psychogenic” reactions, then subsequent analyses of the data could assist to identify which were likely to have been and which were not so likely or were not.  But the less data one has makes the task more difficult.

MHRA Systematically Tampered with 6000 reports of Adverse Reactions To Declare The Vaccine Safe

From April 2008 up to 31st July 2012, the MHRA received a total of 6213 reports of suspected adverse reactions documenting 14,300 symptoms or 2 1/2 symptoms per report.  Nurses contributed more than two-thirds of all reports.  Over 6 million doses of the vaccine were administered.

The way the reports of suspected adverse reactions to GSK’s Cervarix vaccine were tampered with was to ensure the underlying conditions indicated by the reported symptoms could not be identified.  In addition, no clinical follow-up was carried out on any Cervarix Yellow Card report of a suspected adverse reaction. 

To diagnose an individual it is essential to consider all symptoms suffered by that individual and carry out a clinical assessment on a case-by-case basis.  For example, how do you know if you might have flu?  If you have fever, cough, headache, aching muscles and tiredness then you may have flu.

What the MHRA did was to carry out a paper analysis of the Yellow Card reports.  They separated out the symptoms reported for each individual so that it would be impossible for anyone to identify the underlying conditions each individual suffered.  SOURCE: MHRA 29 July 2010 “Suspected Adverse Reaction Analysis”

Here are the 5 categories each symptom was separated into:

A. Injection-site reactions
B. Allergic reactions
C. ‘Psychogenic’ events
D. ‘Other recognised’ reactions
E. not currently recognised

So if we consider by analogy a disease most people know about, flu, if this approach was applied to infectious disease reports each symptom would be split up and put into one or more of these categories.  As the symptoms are no longer linked together it is impossible to say whether anyone was suffering from ‘flu or any other disease.  There would be no way of telling.

Thus, the MHRA set about hiding the numbers and types of suspected ADRs suffered by British schoolchildren. This was not a conspiracy but fact – that is what the MHRA did.

If this approach were adopted to reporting infectious diseases generally the public could have no idea which diseases are present in the population at any time.  There can be numerous infections diseases circulating simultaneously.

For example, a symptom of encephalitis is headache – in the period Sept 08 to 29 July 2010  information from MHRA recorded that in 4703 Yellow Card reports there were 848 reports  which included headache as one of the reported symptoms and  which might therefore be of encephalitis. A “quick and dirty” analysis of the MHRA data issued at that time shows that of just 5 of the 32 symptoms of encephalitis at least 2300 reports include at least one symptom of encephalitis.

But this is what the MHRA said having carried out no clinical investigation or analysis of any of the Yellow Card reports:-

The four cases of encephalitis reported so far, amongst the number of girls immunised, do not exceed  the numbers normally expected in the absence of vaccination. There is therefore no suggestion at present that the vaccine can cause encephalitis.”

SOURCE: MHRA 29 July 2010 “Suspected Adverse Reaction Analysis

This shows

  • MHRA only recorded a report as suspected encephalitis if those specific words appear on the Yellow Card report
  • and confirms MHRA did not consider what underlying conditions are indicated by the symptoms reported on the Yellow Cards

Most reports were by school nurses who are likely only to report the symptoms and not diagnose underlying conditions.

School Head Teachers & Governors

It is obvious from these figures that UK parents are obliged under their Children Act 1989 legal duties to refuse consent.  This also puts head teachers and school governors in a remarkable position for putting children at risk by allowing these vaccination programmes to take place on school premises. Under English law they stand legally in “loco parentis” – in the place of the parents whilst children are under their care in school.

School Nurses & Other Medical Professionals.

Obviously medical practitioners bear a heavy duty of disclosure to obtain informed consent but they are not fulfilling it.  Additionally, it is obvious that anyone proposing to have this vaccine needs to be screened for 1) pre-existing medical conditions putting them at risk and 2) risk of adverse reactions based on prior clinical history.  That is not being done.

Properly informed consent is not being obtained – which legally can give rise to claims for “battery” – not simply negligence and easier to prove.

Parents are being told their 13-year-old girls may be given the vaccine even if the parents refuse consent. Girls of this age might be subject to pressure to persuade them even if parents have refused consent. There are reasons why this may not be lawful under “Gillick competence”.

ANNEX I

LIST OF MHRA REPORTED SYMPTOMS OF ADVERSE REACTIONS TO GSK’S CERVARIX HPV VACCINE – Source MHRA “Suspected Adverse Reaction Analysis” 29th July 2010 

[Also downloadable as a spreadsheet from here 130728 Single list of all Cervarix Yellow Card Reports]
System Organ Class Category A to E Reported event (Preferred Term)

Number of cases

A. Injection-site reactions Pain in extremity 485

485

A. Injection-site reactions Injection site swelling 113

113

A. Injection-site reactions Oedema peripheral 109

109

A. Injection-site reactions Limb discomfort 106

106

A. Injection-site reactions Hypoaesthesia 105

105

A. Injection-site reactions Injection site erythema 85

85

A. Injection-site reactions Injection site pain 81

81

A. Injection-site reactions Erythema 45

45

A. Injection-site reactions Paraesthesia 37

37

A. Injection-site reactions Skin discolouration 33

33

A. Injection-site reactions Injection site rash 32

32

A. Injection-site reactions Injection site mass 29

29

A. Injection-site reactions Injection site reaction 26

26

A. Injection-site reactions Pain 23

23

A. Injection-site reactions Contusion 21

21

A. Injection-site reactions Musculoskeletal stiffness 21

21

A. Injection-site reactions Peripheral coldness 20

20

A. Injection-site reactions Local reaction 19

19

A. Injection-site reactions Injection site inflammation 18

18

A. Injection-site reactions Injection site warmth 18

18

A. Injection-site reactions Pain in extremity 16

16

A. Injection-site reactions Local swelling 15

15

A. Injection-site reactions Sensation of heaviness 15

15

A. Injection-site reactions Injection site haematoma 12

12

A. Injection-site reactions Injection site pruritus 11

11

A. Injection-site reactions Rash macular 10

10

A. Injection-site reactions Oedema peripheral 9

9

A. Injection-site reactions Feeling cold 8

8

A. Injection-site reactions Injection site induration 8

8

A. Injection-site reactions Injection site nodule 8

8

A. Injection-site reactions Livedo reticularis 8

8

A. Injection-site reactions Swelling 8

8

A. Injection-site reactions Injection site anaesthesia 6

6

A. Injection-site reactions Injection site swelling 6

6

A. Injection-site reactions Muscular weakness 6

6

A. Injection-site reactions Myalgia 6

6

A. Injection-site reactions Neck pain 6

6

A. Injection-site reactions Pain 6

6

A. Injection-site reactions Rash 6

6

A. Injection-site reactions Erythema 5

5

A. Injection-site reactions Feeling hot 5

5

A. Injection-site reactions Injection site erythema 5

5

A. Injection-site reactions Pruritus 5

5

A. Injection-site reactions Cyanosis 4

4

A. Injection-site reactions Feeling abnormal 4

4

A. Injection-site reactions Injection site infection 4

4

A. Injection-site reactions Musculoskeletal stiffness 4

4

A. Injection-site reactions Pallor 4

4

A. Injection-site reactions Sensory disturbance 4

4

A. Injection-site reactions Tenderness 4

4

A. Injection-site reactions Asthenia 3

3

A. Injection-site reactions Feeling hot 3

3

A. Injection-site reactions Inflammation 3

3

A. Injection-site reactions Injection site discharge 3

3

A. Injection-site reactions Injection site discolouration 3

3

A. Injection-site reactions Injection site irritation 3

3

A. Injection-site reactions Injection site reaction 3

3

A. Injection-site reactions Injection site urticaria 3

3

A. Injection-site reactions Injection site vesicles 3

3

A. Injection-site reactions Limb immobilisation 3

3

A. Injection-site reactions Musculoskeletal pain 3

3

A. Injection-site reactions Poor peripheral circulation 3

3

A. Injection-site reactions Sensory loss 3

3

A. Injection-site reactions Skin warm 3

3

A. Injection-site reactions Dry skin 2

2

A. Injection-site reactions Grip strength decreased 2

2

A. Injection-site reactions Hypoaesthesia 2

2

A. Injection-site reactions Injected limb mobility decreased 2

2

A. Injection-site reactions Injection site cellulitis 2

2

A. Injection-site reactions Injection site coldness 2

2

A. Injection-site reactions Injection site discolouration 2

2

A. Injection-site reactions Injection site mass 2

2

A. Injection-site reactions Injection site pain 2

2

A. Injection-site reactions Peripheral coldness 2

2

A. Injection-site reactions Pruritus 2

2

A. Injection-site reactions Sensory loss 2

2

A. Injection-site reactions Skin discolouration 2

2

A. Injection-site reactions Skin reaction 2

2

A. Injection-site reactions Skin reaction 2

2

A. Injection-site reactions Tenderness 2

2

A. Injection-site reactions Blister 1

1

A. Injection-site reactions Complex regional pain syndrome 1

1

A. Injection-site reactions Extensive swelling of vaccinated limb 1

1

A. Injection-site reactions Hyperaesthesia 1

1

A. Injection-site reactions Hyperaesthesia 1

1

A. Injection-site reactions Hypokinesia 1

1

A. Injection-site reactions Hypokinesia 1

1

A. Injection-site reactions Immobile 1

1

A. Injection-site reactions Impetigo 1

1

A. Injection-site reactions Injection site abscess 1

1

A. Injection-site reactions Injection site anaesthesia 1

1

A. Injection-site reactions Injection site coldness 1

1

A. Injection-site reactions Injection site discomfort 1

1

A. Injection-site reactions Injection site haematoma 1

1

A. Injection-site reactions Injection site haemorrhage 1

1

A. Injection-site reactions Injection site haemorrhage 1

1

A. Injection-site reactions Injection site joint movement impairment 1

1

A. Injection-site reactions Injection site joint pain 1

1

A. Injection-site reactions Injection site movement impairment 1

1

A. Injection-site reactions Injection site movement impairment 1

1

A. Injection-site reactions Injection site papule 1

1

A. Injection-site reactions Injection site paraesthesia 1

1

A. Injection-site reactions Injection site rash 1

1

A. Injection-site reactions Injection site scab 1

1

A. Injection-site reactions Joint swelling 1

1

A. Injection-site reactions Limb immobilisation 1

1

A. Injection-site reactions Local reaction 1

1

A. Injection-site reactions Local swelling 1

1

A. Injection-site reactions Lymphoedema 1

1

A. Injection-site reactions Mass 1

1

A. Injection-site reactions Mobility decreased 1

1

A. Injection-site reactions Muscle rigidity 1

1

A. Injection-site reactions Muscle spasms 1

1

A. Injection-site reactions Muscle tightness 1

1

A. Injection-site reactions Musculoskeletal pain 1

1

A. Injection-site reactions Nausea 1

1

A. Injection-site reactions Nodule 1

1

A. Injection-site reactions Pain of skin 1

1

A. Injection-site reactions Paraesthesia 1

1

A. Injection-site reactions Peripheral vascular disorder 1

1

A. Injection-site reactions Rash 1

1

A. Injection-site reactions Rash maculo-papular 1

1

A. Injection-site reactions Rash pruritic 1

1

A. Injection-site reactions Scab 1

1

A. Injection-site reactions Sensation of heaviness 1

1

A. Injection-site reactions Sensation of pressure 1

1

A. Injection-site reactions Tremor 1

1

A. Injection-site reactions Urticaria 1

1

A. Injection-site reactions Urticaria 1

1

B. Allergic reactions Rash 130

130

B. Allergic reactions Urticaria 89

89

B. Allergic reactions Pruritus 60

60

B. Allergic reactions Erythema 47

47

B. Allergic reactions Swelling face 42

42

B. Allergic reactions Anaphylactic reaction 41

41

B. Allergic reactions Dyspnoea 33

33

B. Allergic reactions Rash generalised 31

31

B. Allergic reactions Rash pruritic 31

31

B. Allergic reactions Oedema peripheral 29

29

B. Allergic reactions Lip swelling 26

26

B. Allergic reactions Rash macular 24

24

B. Allergic reactions Dizziness 23

23

B. Allergic reactions Hypersensitivity 22

22

B. Allergic reactions Eye swelling 18

18

B. Allergic reactions Paraesthesia oral 17

17

B. Allergic reactions Malaise 15

15

B. Allergic reactions Throat tightness 14

14

B. Allergic reactions Rash 13

13

B. Allergic reactions Swollen tongue 13

13

B. Allergic reactions Chest discomfort 11

11

B. Allergic reactions Rash erythematous 11

11

B. Allergic reactions Feeling hot 9

9

B. Allergic reactions Flushing 9

9

B. Allergic reactions Pruritus generalised 9

9

B. Allergic reactions Dermatitis allergic 8

8

B. Allergic reactions Pallor 8

8

B. Allergic reactions Pharyngeal oedema 8

8

B. Allergic reactions Urticaria 8

8

B. Allergic reactions Fatigue 7

7

B. Allergic reactions Oropharyngeal pain 7

7

B. Allergic reactions Paraesthesia 7

7

B. Allergic reactions Angioedema 6

6

B. Allergic reactions Dysphagia 6

6

B. Allergic reactions Headache 6

6

B. Allergic reactions Inflammation 6

6

B. Allergic reactions Pyrexia 6

6

B. Allergic reactions Throat irritation 6

6

B. Allergic reactions Blister 5

5

B. Allergic reactions Dyspnoea 5

5

B. Allergic reactions Hyperventilation 5

5

B. Allergic reactions Hypoaesthesia oral 5

5

B. Allergic reactions Vomiting 5

5

B. Allergic reactions Wheezing 5

5

B. Allergic reactions Anaphylactic shock 4

4

B. Allergic reactions Eyelid oedema 4

4

B. Allergic reactions Hypersensitivity 4

4

B. Allergic reactions Hypoaesthesia 4

4

B. Allergic reactions Local swelling 4

4

B. Allergic reactions Nausea 4

4

B. Allergic reactions Pain in extremity 4

4

B. Allergic reactions Dermatitis allergic 3

3

B. Allergic reactions Erythema 3

3

B. Allergic reactions Eye pruritus 3

3

B. Allergic reactions Eyelid oedema 3

3

B. Allergic reactions Hyperhidrosis 3

3

B. Allergic reactions Laryngeal oedema 3

3

B. Allergic reactions Limb discomfort 3

3

B. Allergic reactions Nasopharyngitis 3

3

B. Allergic reactions Ocular hyperaemia 3

3

B. Allergic reactions Pain 3

3

B. Allergic reactions Petechiae 3

3

B. Allergic reactions Rash erythematous 3

3

B. Allergic reactions Rash macular 3

3

B. Allergic reactions Rash maculo-papular 3

3

B. Allergic reactions Rash pruritic 3

3

B. Allergic reactions Skin irritation 3

3

B. Allergic reactions Skin reaction 3

3

B. Allergic reactions Somnolence 3

3

B. Allergic reactions Swelling 3

3

B. Allergic reactions Vision blurred 3

3

B. Allergic reactions Abdominal pain 2

2

B. Allergic reactions Abdominal pain upper 2

2

B. Allergic reactions Anaphylactic reaction 2

2

B. Allergic reactions Blister 2

2

B. Allergic reactions Body temperature increased 2

2

B. Allergic reactions Cold sweat 2

2

B. Allergic reactions Dermatitis contact 2

2

B. Allergic reactions Dizziness 2

2

B. Allergic reactions Face oedema 2

2

B. Allergic reactions Feeling cold 2

2

B. Allergic reactions Heart rate increased 2

2

B. Allergic reactions Heart rate irregular 2

2

B. Allergic reactions Heat rash 2

2

B. Allergic reactions Lip swelling 2

2

B. Allergic reactions Peripheral coldness 2

2

B. Allergic reactions Pharyngeal oedema 2

2

B. Allergic reactions Pruritus 2

2